WO2022243574A1 - Inhibiteurs de slc16a3 à base de 3-(phtalazin-1-yl) benzènesulfonamide et leur utilisation thérapeutique - Google Patents

Inhibiteurs de slc16a3 à base de 3-(phtalazin-1-yl) benzènesulfonamide et leur utilisation thérapeutique Download PDF

Info

Publication number
WO2022243574A1
WO2022243574A1 PCT/EP2022/063944 EP2022063944W WO2022243574A1 WO 2022243574 A1 WO2022243574 A1 WO 2022243574A1 EP 2022063944 W EP2022063944 W EP 2022063944W WO 2022243574 A1 WO2022243574 A1 WO 2022243574A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkylene
haloalkyl
carbocyclyl
heterocyclyl
Prior art date
Application number
PCT/EP2022/063944
Other languages
English (en)
Inventor
Vojtech Dvorak
Andrea CASIRAGHI
Giulio Superti-Furga
Original Assignee
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cemm - Forschungszentrum Für Molekulare Medizin Gmbh filed Critical Cemm - Forschungszentrum Für Molekulare Medizin Gmbh
Publication of WO2022243574A1 publication Critical patent/WO2022243574A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention provides 3-(phthalazin-1-yl)benzenesulfonamide-based compounds of formula (I) and pharmaceutically acceptable salts thereof, which have been found to be advantageously potent and selective inhibitors of SLC16A3, as well as their use in the treatment or prevention of SLC16A3-associated diseases/disorders such as cancer.
  • Lactate the end product of glycolysis, is probably best known as a waste product of cellular metabolism.
  • lactate can be also used as an energy source.
  • the Warburg effect which is characteristic for many tumors, is manifested by glycolysis even in aerobic conditions.
  • the metabolism of many cancer cells is connected to a massive increase in glucose consumption and secretion of lactate, allowing for regeneration of NAD* which is required to sustain cellular processes.
  • Elevated lactate levels play many roles in the TME, contributing to many aspects of malignancy, such as stimulation of angiogenesis, cancer cell immune evasion or resistance to therapy (Parks SK et al., Annual Review of Cancer Biology, 2020, 4:141-58).
  • Lactate is transported through the plasma membrane mainly by monocarboxylate transporters (MCTs) of the SLC16 family (Rabinowitz JD et al., Nature Metabolism, 2020, 2(7):566— 71 ).
  • MCTs monocarboxylate transporters
  • the SLC16 family consists of 14 members, out of which 4 are capable of transporting lactate and pyruvate - i.e., SLC16A1, SLC16A3, SLC16A7 and SLC16A8 (Bosshart RD et al., Trends in Biochemical Sciences, 2020, 1-13).
  • SLC16A1 MCT1
  • SLC16A3 MCT4
  • Metabolic symbiosis is established as a response to a rapid growth of tumor and the resulting creation of zones with different oxygen availability.
  • Tumor cells in hypoxic regions metabolize glucose through anaerobic glycolysis, resulting in rapid production of lactate, which is then released to the microenvironment through SLC16A3 (expression of SLC16A3 is upregulated by HI F-1 a).
  • Lactate is then imported to tumor (or stromal) cells in tumor regions with higher oxygen availability through SLC16A1, where it serves as a fuel for mitochondrial metabolism.
  • SLC16A1 secretor cells
  • SLC16A1 has a high affinity for pyruvate
  • the pyruvate affinity of SLC16A3 is low, facilitating a pyruvate conversion into lactate in SLC16A3 expressing cells, which is connected to regeneration of NAD*.
  • SLC16A3 is responsible for lactate export even in microenvironment with high lactate concentration, supporting a role of SLC16A3 in lactate export.
  • Metabolic symbiosis has been reported in pancreatic neuroendocrine cancer, pancreatic ductal adenocarcinoma, lung cancer, breast cancer and colon cancer, suggesting that this may be a general phenomenon in many cancer types and thus an interesting therapeutic target.
  • SLC16A1 While selective and specific inhibitors for SLC16A1 exist - namely AZD3965 and BAY-8002 - and AZD3965 recently underwent clinical trials for the treatment of advanced solid tumors or lymphomas (NCT01791595), selective inhibitors of SLC16A3 are still lacking completely (Quanz M et al., Molecular Cancer Therapeutics, 2018, 17(11):2285— 96). Until recently, the best available inhibitor of SLC16A3 was syrosingopine, which inhibits both SLC16A1 and SLC16A3 with higher selectivity toward SLC16A3 (Benjamin D et al., Cell Reports, 2018, 25(11):3047-3058.e4).
  • SLC16A1 Since inhibition of SLC16A1 is also affecting a T cell function (Murray CM et al., Nature Chemical Biology, 2005, 1 (7):371— 76), targeting SLC16A3 may in some cancers disrupt metabolic symbiosis while preserving functions of immune cells and is thus considered to be a superior target compared to SLC16A1.
  • a novel potent and selective inhibitor of SLC16A3, i.e. VB124 was introduced (Cluntun AA et al., Cell Metabolism, 2020, 1-20).
  • SLC16A3 is frequently upregulated in tumors, compared to normal state, higher expression in many cases correlates with worse prognosis, and in some cases even elevated expression of SLC16A3 was found in metastatic lesions compared to primary tumors.
  • SLC16A3 was reported to play a role in breast cancer (Baenke F et al., Journal of Pathology, 2015, 237(2):152-65). The same study found that expression of SLC16A3 is regulated by PI3K-Akt signaling axis and that the sensitivity to SLC16A3 perturbation was strongest in HER2 + subset of cell lines and in cell lines with high levels of Akt phosphorylation. At the same time, breast cancer cell lines increased glutamine consumption and became more sensitive to inhibition of glutaminase upon SLC16A3 silencing.
  • SLC16A3 expression is elevated in invasive breast cancer and high expression of SLC16A3 correlates with poor prognosis in breast cancer patients (Baenke F et al., Journal of Pathology, 2015, 237(2): 152-65; Doyen J et al., Biochemical and Biophysical Research Communications, 2014, 451 (1):54— 61).
  • basigin CD147
  • SLC16A3 non-small lung cancer
  • NSCLC mouse xenograft model found that development resistance to tyrosine kinase inhibitors (EGFR and MET) is caused by elevated lactate in TME (Apicella M et al., Cell Metabolism, 2018, 28(6):848-865.e6). This effect was diminished by silencing of SLC16A3 in tumor cells, resulting in re- sensitization of tumor cells to therapy.
  • EGFR and MET tyrosine kinase inhibitors
  • SLC16A3 was shown as a therapeutic target for tumors resistant to therapy targeting tumor angiogenesis.
  • resistance to angiogenesis inhibitors develops through metabolic compartmentalization and development of metabolic symbiosis (Allen E et al., Cell Reports, 2016, 15(6): 1144-60; Jimenez-Valerio G et al., Cell Reports, 2016, 15(6): 1134-43; Pisarsky L et al., Cell Reports, 2016, 15(6):1161-74).
  • These results were confirmed also in clinical samples from renal cancer (Jimenez-Valerio G et al., Cell Reports, 2016, 15(6): 1134-43).
  • SLC16A3 is one of the most overexpressed genes in renal cancer, and was found to be an essential gene for renal cancer cell lines in genome-wide siRNA screen (Gerlinger M et al. Journal of Pathology, 2012, 227(2): 146-56).
  • the study also assessed SLC16A3 expression in clear cell renal carcinoma patient biopsies by immunohistochemistry and found that SLC16A3 was detectable in a majority of samples, and that expression correlates with Fuhrman nuclear grade. Moreover, metastatic lesions had significantly higher SLC16A3 mRNA levels compared to primary tumors.
  • SLC16A3 was also shown to play a role in bladder cancer. Expression of SLC16A3 was elevated in primary tumors compared to benign urothelium and high SLC16A3 expression associates with inferior overall survival (Todenhofer T et al., Molecular Cancer Therapeutics, 2018, 17(12):2746— 55). Silencing of SLC16A3 reduced growth of bladder cancer both in vitro and in orthotopic xenograft mouse model.
  • a study focusing on the role of SLC16A3 in pancreatic cancer showed that expression of SLC16A3 is elevated in tumors compared to normal tissue and elevated expression of SLC16A3 correlates with worse prognosis (no matter if high SLC16A3 expression is found in the tumor stroma or cancer cells) (Baek GH et al., Cell Reports, 2014, 9(6):2233-49).
  • silencing of SLC16A3 in pancreatic cell lines results in metabolic crisis, which can be compensated by upregulation of mitochondrial metabolism, switch from glucose to glutamine as an energy source, or by induction of macropinocytosis or autophagy.
  • silencing of SLC16A3 resulted in cell death in cell lines with high endogenous expression of SLC16A3.
  • inhibition of mitochondrial complex I phenformin, rotenone
  • macropinocytosis EIPA
  • autophagy chloroquine
  • lactate transporters from the SLC16 family was also investigated in colorectal cancer.
  • cells obtained from malignant ascites metastasis of colorectal cancer patients showed high overexpression of SLC16A3 and were sensitive to silencing of SLC16A3.
  • SLC16A3 has been implicated not only in cancer but also in other diseases.
  • a recent study showed that SLC16A3 is a therapeutic target for heart failure and the use of a new selective and potent SLC16A3 inhibitor, VB-124, can prevent cardiac hypertrophy (both in vitro and in a mouse model) caused by disbalance of the pyruvate-lactate axis (Cluntun AA et al., Cell Metabolism, 2020, 1-20; Cluntun AA et al., Cell Metabolism, 2021, 33(3):629-648.e10).
  • RA rheumatoid arthritis
  • SLC9A1, V-ATPase, SLC16A1 and SLC16A3 synovial fibroblast of RA patients
  • OASFs synovial fibroblasts of osteoarthritis patients
  • SLC16A3 has further been described as a potential target for the therapy of inflammatory bowel disease (He L et al., Dis Markers, 2018, 2018:2649491; Zhang S et al., Cell Prolif, 2019, 52(6):e12673) and Alzheimer’s disease (Hong P et al., Neurotoxicology, 2020, 76:191-199).
  • SLC16A3 inhibitors and therapeutic uses thereof have been proposed in WO 2017/196936, WO 2018/111904, WO 2019/215316 and US 2019/0352282.
  • WO 2016/081464 relates to inhibitors of the MOT (SLC16) family in general, without addressing the crucial question of specificity for SLC16A3.
  • two papers using the SLC16A3 inhibitor VB124 were published (Bonglack EN et al., BioRxiv, 2020, 12.04.410563; Cluntun AA et al., Cell Metabolism, 2020, 1-20).
  • AstraZeneca presented data on their SLC16A3 inhibitor AZD0095 at the AACR Annual Meeting 2019 in Atlanta (Critchlow SE et al., Cancer Res, 2019, 79(13 Suppl): Abstract 1207, doi :10.1158/1538- 7445.AM2019-1207).
  • the present invention addresses this need and provides compounds that have been found to exhibit a highly potent and selective inhibitory effect on SLC16A3, which renders these compounds particularly advantageous for therapeutic use, including in the treatment or prevention of cancer and other SLC16A3-associated diseases/disorders.
  • the invention thus solves the problem of providing improved SLC16A3 inhibitors.
  • the present invention provides a compound of the following formula (I) or a pharmaceutically acceptable salt thereof:
  • the group X is selected from -N(R 2 )-R 1 , -O-R 1 , -S-R 1 , and -CH 2 -R 1 .
  • R 1 is a group -L-R N1 .
  • R 1 is a group -L-R N1
  • R 2 is a group R N2
  • R 1 and R 2 are mutually joined to form, together with the nitrogen atom that they are attached to, a heterocycloalkyl which is optionally substituted with one or more groups R 11 .
  • L is selected from a covalent bond, C 1-5 alkylene, C 2-5 alkenylene, and C 2-5 alkynylene, wherein said alkylene, said alkenylene and said alkynylene are each optionally substituted with one or more groups independently selected from halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH 2 , -NH( C 1-5 alkyl), and -N( C 1-5 alkyl)( C 1-5 alkyl), and further wherein one or more -CH 2 - units comprised in said alkylene, said alkenylene or said alkynylene are each optionally replaced by a group independently selected from -O-, -NH-, -N(C 1-5 alkyl)- , -CO-, -S-, -SO-, and
  • R N1 is carbocyclyl or heterocyclyl, wherein said carbocyclyl or said heterocyclyl is optionally substituted with one or more groups R N11 .
  • R N2 is selected from hydrogen, C 1-5 alkyl and -CO-(C 1-5 alkyl), wherein said alkyl or the alkyl in said -CO-(C 1-5 alkyl) is optionally substituted with one or more groups independently selected from halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), and -N(C 1-5 alkyl)(C 1-5 alkyl).
  • R 3 and R 4 are each independently selected from hydrogen, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, -(C 0-8 alkylene)-carbocyclyl, and -(C 0-8 alkylene)-heterocyclyl, wherein said alkyl, said alkenyl, said alkynyl, the alkylene in said -(C 0-8 alkylene)-carbocyclyl, and the alkylene in said -(C 0-8 alkylene)-heterocyclyl are each optionally substituted with one or more groups R 31 , wherein the carbocyclyl in said -(C 0-8 alkylene)-carbocyclyl and the heterocyclyl in said -(C 0-8 alkylene)-heterocyclyI are each optionally substituted with one or more groups R Cyc , and optionally wherein one or more -CH 2 - units comprised in the C 0-8 al
  • Each R 31 is independently selected from -OH, -O(C 1-5 alkyl), -O(C 1-5 alkylene)-OH, -O(C 1-5 alkylene)-O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -S(C 1-5 alkylene)-SH, -S(C 1-5 alkylene)-S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), -NH-OH, -N(C 1-5 alkyl)-OH, -NH-O(C 1-5 alkyl), -N(C 1-5 alkyl)-O(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -ON, -OHO, -CO-(C 1-5 alkyl), -COOK, -
  • Each R 11 , each R N11 , each R 32 , each R 5 and each R 6 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -(C 0-3 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-O(C 1-5 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-S(C 1-5 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-NH2, -(C 0-3 alky
  • Each R Cyc is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -OH, -O(C 1-5 alkyl), -O(C 1-5 alkylene)- OH, -O(C 1-5 alkylene)-O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -S(C 1-5 alkylene)-SH, -S(C 1-5 alkylene)-S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), -NH-OH, -N(C 1-5 alkyl)-OH, -NH-O(C 1-5 alkyl), -N(C 1-5 alkyl)-O(C 1-5 alkyl), halogen, C 1-5 haloalky
  • Each L C1 is independently selected from a covalent bond, C 1-5 alkylene, C 2-5 alkenylene, and C 2-5 alky nylene, wherein said alkylene, said alkenylene and said alkynylene are each optionally substituted with one or more groups independently selected from halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl), and -N(C 1-5 alkyl)(C 1-5 alkyl), and further wherein one or more -CH 2 - units comprised in said alkylene, said alkenylene or said alkynylene are each optionally replaced by a group independently selected from -O-, -NH-, -N(C 1-5 alkyl)-, -CO-, -S-, -SO-
  • Each R C1 is independently selected from -OH, -O(C 1-5 alkyl), -O(C 1-5 alkylene)-OH, -O(C 1-5 alkylene)-O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -S(C 1-5 alkylene)-SH, -S(C 1-5 alkylene)-S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), -NH-OH, -N(C 1-5 alkyl)-OH, -NH-O(C 1-5 alkyl), -N(C 1-5 alkyl)-O(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO(C 1-5 alkyl), -COOH, -C
  • the present invention also relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. Accordingly, the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the aforementioned entities and a pharmaceutically acceptable excipient, for use in therapy (or for use as a medicament).
  • the invention further relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the aforementioned entities and a pharmaceutically acceptable excipient, for use in the treatment or prevention of an SLC16A3-associated disease/disorder (or an SLC16A3- mediated disease/disorder).
  • the invention in particular provides a pharmaceutical composition comprising, as an active ingredient, a compound of formula (I) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient, for use in the treatment or prevention of an SLC16A3-associated disease/disorder.
  • the present invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment or prevention of an SLC16A3-associated disease/disorder.
  • the invention likewise relates to a method of treating or preventing an SLC16A3-associated disease/disorder, the method comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the aforementioned entities in combination with a pharmaceutically acceptable excipient, to a subject (preferably a human) in need thereof. It will be understood that a therapeutically effective amount of the compound of formula (I) or the pharmaceutically acceptable salt thereof (or of the pharmaceutical composition) is to be administered in accordance with this method.
  • the disease or disorder to be treated or prevented with a compound of formula (I) or a pharmaceutically acceptable salt thereof (or a corresponding pharmaceutical composition) in accordance with the present invention encompasses any SLC16A3-associated disease/disorder, including also any of the diseases/disorders mentioned herein above in the introduction (background section) of the present specification.
  • the disease/disorder to be treated or prevented in accordance with the invention is selected from cancer, an inflammatory disorder (e.g., rheumatoid arthritis or inflammatory bowel disease), a cardiovascular disorder (e.g., heart failure or cardiac hypertrophy), a fibrotic disorder (e.g., pulmonary fibrosis (including idiopathic pulmonary fibrosis), liver fibrosis, cystic fibrosis, renal fibrosis, peritoneal fibrosis, pancreatic fibrosis, intestinal fibrosis, cardiac fibrosis, or skin fibrosis), and Alzheimer’s disease.
  • an inflammatory disorder e.g., rheumatoid arthritis or inflammatory bowel disease
  • a cardiovascular disorder e.g., heart failure or cardiac hypertrophy
  • a fibrotic disorder e.g., pulmonary fibrosis (including idiopathic pulmonary fibrosis), liver fibrosis, cystic fibrosis, renal
  • the SLC16A3-associated disease/disorder to be treated or prevented may also be, e.g., muscular dystrophy, systemic sclerosis, metabolic syndrome, diabetes, dyslipidemia, fatty liver disease, non-alcoholic steatohepatitis, obesity, or insulin resistance.
  • the invention particularly relates to the treatment or prevention of cancer.
  • the cancer to be treated or prevented in accordance with the present invention is preferably selected from lung cancer (e.g., non-small cell lung cancer or small cell lung cancer; particularly non-small cell lung cancer), cervical cancer (e.g., cervical squamous cell carcinoma or endocervical adenocarcinoma), colorectal cancer, colon cancer (e.g., colon adenocarcinoma), rectal cancer (e.g., rectum adenocarcinoma), glioblastoma (e.g., glioblastoma multiforme), gastric cancer (e.g., stomach adenocarcinoma), ovarian cancer (e.g., ovarian serous cystadenocarcinoma), head and neck squamous cell carcinoma, oral squamous cell carcinoma, breast cancer (e.g., invasive breast cancer, triple negative breast cancer, or HER2-positive breast cancer), prostate cancer (e.g., prostate adenocarcinoma),
  • the cancer many also be, e.g., adult T-cell leukemia, blastoma, bone cancer, brain cancer, carcinoma, myeloid sarcoma, esophageal cancer, gastrointestinal cancer, glioma, gallbladder cancer, Hodgkin's lymphoma, intestinal cancer, laryngeal cancer, leukemia, lymphoma, mesothelioma, ocular cancer, optic nerve tumor, pituitary tumor, primary central nervous lymphoma, pharyngeal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, T-cell lymphoma, testicular cancer, throat cancer, urogenital cancer, urothelial carcinoma, uterine cancer, vaginal cancer, or Wilms' tumor.
  • adult T-cell leukemia blastoma, bone cancer, brain cancer, carcinoma, myeloid sarcoma, esophageal cancer, gastrointestinal cancer, glioma, gallbladder cancer
  • the cancer is selected from lung cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, and pancreatic cancer.
  • the cancer (including any one of the specific cancers described above) may also be an angiogenesis inhibitor-resistant cancer.
  • the cancer may also be a glycolysis-dependent cancer or a cancer which does not depend on glycolysis.
  • the compounds provided herein can also be used for re-sensitization of cancers/tumors to anti-angiogenic therapy. Accordingly, the invention also relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof (or a corresponding pharmaceutical composition) for use in re-sensitizing a cancer (particularly a tumorous cancer) to anti-angiogenic therapy.
  • the invention likewise relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof (or a corresponding pharmaceutical composition) for use in treating or preventing cancer (including any of the specific cancers described herein above), wherein said compound (or said pharmaceutical composition) is administered in combination with an angiogenesis inhibitor.
  • the present invention furthermore relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as an inhibitor of SLC16A3 (or MCT4) in research, particularly as a research tool compound for inhibiting SLC16A3.
  • the invention refers to the in vitro use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as an SLC16A3 inhibitor (or an MCT4 inhibitor) and, in particular, to the in vitro use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as a research tool compound acting as an SLC16A3 inhibitor (or an MCT4 inhibitor).
  • the invention likewise relates to a method, particularly an in vitro method, of inhibiting SLC16A3, the method comprising the application of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention further relates to a method of inhibiting SLC16A3, the method comprising applying a compound of formula (I) or a pharmaceutically acceptable salt thereof to a test sample (e.g., a biological sample) or a test animal (i.e. , a non-human test animal).
  • the invention also refers to a method, particularly an in vitro method, of inhibiting SLC16A3 in a sample (e.g., a biological sample), the method comprising applying a compound of formula (I) or a pharmaceutically acceptable salt thereof to said sample.
  • the present invention further provides a method of inhibiting SLC16A3, the method comprising contacting a test sample (e.g., a biological sample) or a test animal (i.e., a non-human test animal) with a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • a test sample e.g., a biological sample
  • test animal i.e., a non-human test animal
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof include, without being limited thereto: a cell, a cell culture or a cellular or subcellular extract; biopsied material obtained from an animal (e.g., a human), or an extract thereof; or blood, serum, plasma, saliva, urine, feces, or any other body fluid, or an extract thereof.
  • in vitrd* is used in this specific context in the sense of “outside a living human or animal body”, which includes, in particular, experiments performed with cells, cellular or subcellular extracts, and/or biological molecules in an artificial environment such as an aqueous solution or a culture medium which may be provided, e.g., in a flask, a test tube, a Petri dish, a microtiter plate, etc.
  • an aqueous solution or a culture medium which may be provided, e.g., in a flask, a test tube, a Petri dish, a microtiter plate, etc.
  • the group X is selected from -N(R 2 )-R 1 , -O-R 1 , -S-R 1 , and -CH 2 -R 1 .
  • X is selected from -N(R 2 )-R 1 , -O-R 1 , and -S-R 1 . More preferably, X is -N(R 2 )-R 1 . Accordingly, it is particularly preferred that the compound of formula (I) has the following structure:
  • R 1 is a group -L-R N1 .
  • R 1 is a group -L-R N1
  • R 2 is a group R N2
  • R 1 and R 2 are mutually joined to form, together with the nitrogen atom that they are attached to, a heterocycloalkyl which is optionally substituted with one or more (e.g., one, two, three or four) groups R 11 .
  • R 1 is a group -L-R N1
  • R 2 is a group R N2 .
  • L is selected from a covalent bond, C 1-5 alkylene, C 2-5 alkenylene, and C 2-5 alkynylene, wherein said alkylene, said alkenylene and said alkynylene are each optionally substituted with one or more (e.g., one, two or three) groups independently selected from halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl), and -N(C 1-5 alkyl)(C 1-5 alkyl), and further wherein one or more (e.g., one, two or three) -CH 2 - units comprised in said alkylene, said alkenylene or said alkynylene are each optionally replaced by a group independently selected from -O-, -NH-, -N(C 1-5 al
  • L is a covalent bond or C 1-5 alkylene, wherein said alkylene is optionally substituted with one or more groups independently selected from halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), and -N(C 1-5 alkyl)(C 1-5 alkyl). More preferably, L is a covalent bond or C 1-5 alkylene. Even more preferably, L is a covalent bond or -(CH 2 ) 1-5 -.
  • L is selected from a covalent bond, -CH 2 -, -CH 2 CH 2 - and -CH 2 CH 2 CH 2 -.
  • L may be -CH 2 - or -CH 2 CH 2 -.
  • L is -CH 2 -.
  • R N1 is carbocyclyl or heterocyclyl, wherein said carbocyclyl or said heterocyclyl is optionally substituted with one or more (e.g., one, two, three or four) groups R N11 .
  • R N1 is selected from aryl (e.g., phenyl or naphthyl), heteroaryl (e.g., pyridinyl or 1,3-benzodioxolyl, including 1,3-benzodioxol-5-yl), cycloalkyl (e.g., cyclohexyl) and heterocycloalkyl (e.g., piperidinyl or morpholinyl, including piperidin-1-yl or morpholin-4-yl), wherein said aryl, said heteroaryl, said cycloalkyl and said heterocycloalkyl are each optionally substituted with one or more R N11 .
  • aryl e.g., phenyl or naphthyl
  • heteroaryl e.g., pyridinyl or 1,3-benzodioxolyl, including 1,3-benzodioxol-5-yl
  • cycloalkyl e
  • R N1 is aryl (e.g., phenyl) or heteroaryl (e.g., monocyclic heteroaryl), wherein said aryl or said heteroaryl is optionally substituted with one or more R N11 .
  • R N1 is phenyl which is optionally substituted with one or more R N11 .
  • L is -CH 2 - and R N1 is phenyl which is optionally substituted with one or more R N11 .
  • R N2 is selected from hydrogen, C 1-5 alkyl and -CO-(C 1-5 alkyl), wherein said alkyl or the alkyl in said -CO-(C 1-5 alkyl) is optionally substituted with one or more (e.g., one, two or three) groups independently selected from halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), and -N(C 1-5 alkyl)(C 1-5 alkyl).
  • one or more groups independently selected from halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH 2
  • R N2 is selected from hydrogen, C 1-5 alkyl and -CO-(C 1-5 alkyl). More preferably, R N2 is hydrogen or C 1-5 alkyl (e.g., methyl or ethyl). Even more preferably, R N2 is hydrogen.
  • R 1 is a group -L-R N1
  • R 2 is a group R N2
  • R 1 and R 2 may be mutually joined to form, together with the nitrogen atom that they are attached to, a heterocycloalkyl which is optionally substituted with one or more groups R 11 .
  • the heterocycloalkyl formed from R 1 and R 2 is preferably a monocyclic heterocycloalkyl having 5 to 8 ring members (i.e., 5, 6, 7 or 8 ring atoms), more preferably a monocyclic 5- or 6-membered heterocycloalkyl, even more preferably a monocyclic 6-membered heterocycloalkyl.
  • the heterocycloalkyl contains at least one nitrogen ring atom, i.e., the nitrogen atom that R 1 and R 2 are attached to.
  • the heterocycloalkyl may, for example, contain 0, 1, 2 or 3 further ring heteroatoms (preferably 0 or 1 further ring heteroatom) selected independently from oxygen (0), sulfur (S) and nitrogen (N), whereby the remaining ring atoms are carbon atoms.
  • Preferred examples of the heterocycloalkyl formed from R 1 and R 2 include, in particular, piperidinyl (e.g., piperidin-1-yl), piperazinyl (e.g., piperazin-1-yl) or morpholinyl (e.g., morpholin-4-yl).
  • Said piperazinyl which is optionally substituted with one or more R 11 may be, e.g., 4-(C 1-5 alkyl)-piperazin-1-yl (e.g., 4-methylpiperazin-1-yl) which is optionally further substituted with one or more (e.g., one or two) groups R 11 .
  • R 3 and R 4 are each independently selected from hydrogen, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, -(C 0-8 alkylene)-carbocyclyl, and -(C 0-8 alkylene)-heterocyclyl, wherein said alkyl, said alkenyl, said alkynyl, the alkylene in said -(C 0-8 alkylene)-carbocyclyl, and the alkylene in said -(C 0-8 alkylene)-heterocyclyl are each optionally substituted with one or more (e.g., one, two or three) groups R 31 , wherein the carbocyclyl in said -(C 0-8 alkylene)-carbocyclyl and the heterocyclyl in said -(C 0-8 alkylene)-heterocyclyl are each optionally substituted with one or more (e.g., one, two, three or four) groups R Cyc
  • Each R 31 is independently selected from -OH, -O(C 1-5 alkyl), -O(C 1-5 alkylene)-OH, -O(C 1-5 alkylene)-O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -S(C 1-5 alkylene)-SH, -S(C 1-5 alkylene)-S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), -NH-OH, -N(C 1-5 alkyl)-OH, -NH-O(C 1-5 alkyl), -N(C 1-5 alkyl)-O(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CMC, -CO-(C 1-5 alkyl), -COCH, -
  • each R 31 is independently selected from -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), and -CN.
  • R 3 and R 4 are each independently selected from hydrogen, C 1-8 alkyl, C 2-8 alkenyl, -(C 0-8 alkylene)-carbocyclyl, and -(C 0-8 alkylene)-heterocyclyl, wherein said alkyl, said alkenyl, the alkylene in said -(C 0-8 alkylene)-carbocyclyl, and the alkylene in said -(C 0-8 alkylene)-heterocyclyl are each optionally substituted with one or more groups R 31 , and wherein the carbocyclyl in said -(C 0-8 alkylene)-carbocyclyl and the heterocyclyl in said -(C 0-8 alkylene)-heterocyclyl are each optionally substituted with one or more groups R Cyc .
  • R 3 and R 4 are each independently selected from hydrogen, C 1-5 alkyl, -(C 0-5 alkylene)-carbocyclyl, and -(C 0-5 alkylene)-heterocyclyl, wherein said alkyl, the alkylene in said -(C 0-5 alkylene)-carbocyclyl, and the alkylene in said -(C 0-5 alkylene)-heterocyclyl are each optionally substituted with one or more groups R 31 , and wherein the carbocyclyl in said -(C 0-5 alkylene)-carbocyclyl and the heterocyclyl in said -(C 0-5 alkylene)-heterocyclyl are each optionally substituted with one or more groups R Cyc .
  • R 3 and R 4 are each independently selected from hydrogen, C 1-5 alkyl, -(C 1-5 alky lene)-O H, -(C 1-5 alky lene)-O(C 1-5 alkyl), -(C 1-5 alky lene)-SH, -(C 1-5 alky lene)-S(C 1-5 alkyl), -(C 1-5 alkylene)-NH 2 , -(C 1-5 alkylene)-NH(C 1-5 alkyl), -(C 1-5 alkylene)-N(C 1-5 alkyl)(C 1-5 alkyl), -(C 1-5 alkylene)-halogen, -(C 1-5 alkylene)-(C 1-5 haloalkyl), -(C 1-5 alkylene)-O-(C 1-5 haloalkyl), -(C 1-5 alkylene)-CN, -(C 0-5 alkylene)-aryl, -(C 0-5 alkyl
  • R 3 and R 4 are not mutually joined, it is preferred that one of R 3 and R 4 is hydrogen or C 1-8 alkyl (e.g., C 1-5 alkyl, including methyl or ethyl), preferably hydrogen, and the other one of R 3 and R 4 is as defined in any of the general or preferred definitions of R 3 and R 4 described herein above.
  • one of R 3 and R 4 is hydrogen or C 1-8 alkyl (e.g., C 1-5 alkyl, including methyl or ethyl), preferably hydrogen
  • the other one of R 3 and R 4 is as defined in any of the general or preferred definitions of R 3 and R 4 described herein above.
  • one of R 3 and R 4 is hydrogen or C 1-8 alkyl, preferably hydrogen; and the other one of R 3 and R 4 is selected from hydrogen, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, -(C 0-8 alkylene)-carbocyclyl, and -(C 0-8 alkylene)-heterocyclyl, wherein said alkyl, said alkenyl, said alkynyl, the alkylene in said -(C 0-8 alkylene)-carbocyclyl, and the alkylene in said -(C 0-8 alkylene)-heterocyclyl are each optionally substituted with one or more R 31 , wherein the carbocyclyl in said -(C 0-8 alky lene)-carbocyclyl and the heterocyclyl in said -(C 0-8 al kylene)-heterocyclyl are each optionally substituted with one
  • one of R 3 and R 4 is hydrogen or C 1-5 alkyl, preferably hydrogen; and the other one of R 3 and R 4 is selected from hydrogen, C 1-5 alkyl, -(C 0-5 alky lene)-carbocyclyl , and -(C 0-5 alkylene)-heterocyclyl, wherein said alkyl, the alkylene in said -(C 0-5 alkylene)-carbocyclyl, and the alkylene in said -(C 0-5 alkylene)-heterocyclyl are each optionally substituted with one or more R 31 , and wherein the carbocyclyl in said -(C 0-5 alkylene)-carbocyclyl and the heterocyclyl in said -(C 0-5 alkylene)-heterocyclyl are each optionally substituted with one or more R Cyc .
  • one of R 3 and R 4 is hydrogen or C 1-5 alkyl, preferably hydrogen, and the other one of R 3 and R 4 is selected from hydrogen, C 1-5 alkyl, -(C 1-5 alkylene)-OH, -(C 1-5 alkylene)-O(C 1-5 alkyl), -(C 1-5 alkylene)-SH, -(C 1-5 alkylene)-S(C 1-5 alkyl), -(C 1-5 alkylene)-NH2, -(C 1-5 alkylene)-NH(C 1-5 alkyl), -(C 1-5 alkylene)-N(C 1-5 alkyl)(C 1-5 alkyl), -(C 1-5 alkylene)-halogen, -(C 1-5 alkylene)-(C 1-5 haloalkyl), -(C 1-5 alkylene)-O-(C 1-5 haloalkyl), -(C 1-5 alkylene)-CN, -(C 0-5
  • the heterocycloalkyl formed from R 3 and R 4 is a 5- to 10-membered heterocycloalkyl (which may be monocyclic or bicyclic), more preferably a monocyclic 5-, 6- or 7-membered heterocycloalkyl, even more preferably a monocyclic 6-membered heterocycloalkyl.
  • the heterocycloalkyl contains at least one nitrogen ring atom, i.e., the nitrogen atom that R 3 and R 4 are attached to.
  • the heterocycloalkyl may, for example, contain 0, 1, 2 or 3 further ring heteroatoms (preferably 0 or 1 further ring heteroatoms) selected independently from oxygen (0), sulfur (S) and nitrogen (N), whereby the remaining ring atoms are carbon atoms.
  • Preferred examples of the heterocycloalkyl formed from R 3 and R 4 include, in particular, piperidin-1-yl or morpholin-4-yl.
  • R 3 and R 4 may also be selected so as to correspond to the respective groups contained in any one of the specific compounds described herein below in the examples.
  • R 3 may be hydrogen and R 4 may be -CH 2 -tetrahydrofuranyl (e.g., -CH 2 -(tetrahydrofuran-2-yl), which may be present, e.g., as the R-isomer or the S-isomer); or R 3 may be hydrogen and R 4 may be tert-butyl; or R 3 may be hydrogen and R 4 may be -C(CH 3 )2- CH 2 -OH; or R 3 may be hydrogen and R 4 may be -CH 2 CH 2 OH; or R 3 may be hydrogen and R 4 may be -CH 2 -pyridinyl (e.g., -CH 2 -(pyridin-2-yl)); or R 3 may be hydrogen and R 4 may be -CH 2 -COO-CH 2 CH 3 ; or R
  • Each R 11 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -(C 0-3 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-O(C 1-5 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-S(C 1-5 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-NH2, -(C 0-3 alkylene)-NH(C 1-5 alkyl), -(C 0-3 al
  • each R 11 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -OH, -O(C 1-5 alkyl), -O(C 1-5 alkylene)-OH, -O(C 1-5 alkylene)-O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -S(C 1-5 alkylene)-SH, -S(C 1-5 alkylene)-S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), -NH-OH, -N(C 1-5 alkyl)-OH, -NH-O(C 1-5 alkyl), -N(C 1-5 alkyl)-O(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), halogen,
  • each R 11 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -O(C 1-5 alkyl), -S(C 1-5 alkyl), -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -(C 0-3 alkylene)-CN, -(C 0-3 alkylene)-carbocyclyl, and -(C 0-3 alkylene)-heterocyclyl, wherein the carbocyclyl group in said -(C 0-3 alkylene)-carbocyclyl and the heterocyclyl group in said -(C 0-3 alky lene)-heterocyclyI are each optionally substituted with one or more groups R Cyc , and further wherein one or two -CH 2 -
  • each R 11 is independently selected from C 1-5 alkyl, -O(C 1-5 alkyl), -S(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -ON, -(C 0-3 alkylene)-carbocyclyl, and -(C 0-3 alkylene)-heterocyclyl, wherein the carbocyclyl in said -(C 0-3 alkylene)-carbocyclyl and the heterocyclyl in said -(C 0-3 alky lene)-heterocyclyl are each optionally substituted with one or more groups R Cyc .
  • each R 11 is independently selected from C 1-5 alkyl (e.g., methyl or ethyl), -O(C 1-5 alkyl), -S(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), and -ON.
  • Each R N11 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -(C 0-3 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-O(C 1-5 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-S(C 1-5 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-NH2, -(C 0-3 alkylene)-NH(C 1-5 alkyl), -(C 0-3
  • each R N11 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -OH, -O(C 1-5 alkyl), -O(C 1-5 alkylene)-OH, -O(C 1-5 alkylene)-O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -S(C 1-5 alkylene)-SH, -S(C 1-5 alkylene)-S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), -NH-OH, -N(C 1-5 alkyl)-OH, -NH-O(C 1-5 alkyl), -N(C 1-5 alkyl)-O(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl),
  • each R N11 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -O(C 1-5 alkyl), -S(C 1-5 alkyl), -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -(C 0-3 alkylene)-CN, -(C 0-3 alkylene)-carbocyclyl, and -(C 0-3 alkylene)-heterocyclyl, wherein the carbocyclyl group in said -(C 0-3 alkylene)-carbocyclyl and the heterocyclyl group in said -(C 0-3 alky lene)-heterocyclyI are each optionally substituted with one or more groups R Cyc , and further wherein one or two -CH 2
  • each R N11 is independently selected from C 1-5 alkyl, -O(C 1-5 alkyl), -S(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -ON, -(C 0-3 alkylene)-carbocyclyl, and -(C 0-3 alkylene)-heterocyclyl, wherein the carbocyclyl in said -(C 0-3 alkylene)-carbocyclyl and the heterocyclyl in said -(C 0-3 alky lene)-heterocyclyl are each optionally substituted with one or more groups R Cyc .
  • each R N11 is independently selected from C 1-5 alkyl (e.g., methyl or ethyl), -O(C 1-5 alkyl), -S(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), and -ON.
  • R N1 is phenyl which is optionally substituted with one or more R N11
  • the corresponding group(s) R N11 may be attached to said phenyl in any of positions 2, 3, 4, 5 and/or 6.
  • said substituent R N11 may be attached to the phenyl ring (i) in 2- or 6-position (i.e., ortho), (ii) in 3- or 5-position (i.e. , meta), or (iii) in 4-position (i.e., para), preferably in 3-position or 4-position.
  • substituents R N11 may be attached to the phenyl ring (i) in 2-position and 3-position, (ii) in 2-position and 4-position, (iii) in 2-position and 5-position, (iv) in 2-position and 6-position, (v) in 3-position and 4-position, or (vi) in 3-position and 5-position; preferably in 3-position and 4-position, or in 3-position and 5-position.
  • substituents R N11 may be attached to the phenyl ring (i) in 2-position, 3-position and 4-position, (ii) in 2-position, 3-position and 5-position, (iii) in 2-position, 3-position and 6-position, (iv) in 2-position, 4-position and 5-position, (v) in 2-position, 4-position and 6-position, or (vi) in 2-position, 3-position and 5-position.
  • Each R 32 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -(C 0-3 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-O(C 1-5 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-S(C 1-5 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-NH2, -(C 0-3 alkylene)-NH(C 1-5 alkyl), -(C 0-3 al
  • each R 32 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -OH, -O(C 1-5 alkyl), -O(C 1-5 alkylene)-OH, -O(C 1-5 alkylene)-O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -S(C 1-5 alkylene)-SH, -S(C 1-5 alkylene)-S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), -NH-OH, -N(C 1-5 alkyl)-OH, -NH-O(C 1-5 alkyl), -N(C 1-5 alkyl)-O(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), halogen,
  • each R 32 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -O(C 1-5 alkyl), -S(C 1-5 alkyl), -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -(C 0-3 alkylene)-CN, -(C 0-3 alkylene)-carbocyclyl, and -(C 0-3 alkylene)-heterocyclyl, wherein the carbocyclyl group in said -(C 0-3 alkylene)-carbocyclyl and the heterocyclyl group in said -(C 0-3 alky lene)-heterocyclyI are each optionally substituted with one or more groups R Cyc , and further wherein one or two -CH 2 -
  • each R 32 is independently selected from C 1-5 alkyl, -O(C 1-5 alkyl), -S(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -(C 0-3 alkylene)-carbocyclyl, and -(C 0-3 alkylene)-heterocyclyl, wherein the carbocyclyl in said -(C 0-3 alkylene)-carbocyclyl and the heterocyclyl in said -(C 0-3 alky lene)-heterocyclyl are each optionally substituted with one or more groups R Cyc .
  • each R 32 is independently selected from C 1-5 alkyl (e.g., methyl or ethyl), -O(C 1-5 alkyl), -S(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), and -CN.
  • Each R 5 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyI, -(C 0-3 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-O(C 1-5 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-S(C 1-5 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-NH 2 , -(C 0-3 alkylene)-NH(C 1-5 alkyl), -(C 0
  • each R 5 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -OH, -O(C 1-5 alkyl), -O(C 1-5 alkylene)-OH, -O(C 1-5 alkylene)-O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -S(C 1-5 alkylene)-SH, -S(C 1-5 alkylene)-S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), -NH-OH, -N(C 1-5 alkyl)-OH, -NH-O(C 1-5 alkyl), -N(C 1-5 alkyl)-O(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), halogen,
  • each R 5 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -O(C 1-5 alkyl), -S(C 1-5 alkyl), -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -(C 0-3 alkylene)-CN, -(C 0-3 alkylene)-carbocyclyl, and -(C 0-3 alkylene)-heterocyclyl, wherein the carbocyclyl group in said -(C 0-3 alkylene)-carbocyclyl and the heterocyclyl group in said -(C 0-3 alky lene)-heterocyclyI are each optionally substituted with one or more groups R Cyc , and further wherein one or two -CH 2 -
  • each R 5 is independently selected from C 1-5 alkyl, -O(C 1-5 alkyl), -S(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -(C 0-3 alkylene)-carbocyclyl, and -(C 0-3 alkylene)-heterocyclyl, wherein the carbocyclyl in said -(C 0-3 alkylene)-carbocyclyl and the heterocyclyl in said -(C 0-3 alky lene)-heterocyclyl are each optionally substituted with one or more groups R Cyc .
  • each R 5 is independently selected from C 1-5 alkyl (e.g., methyl or ethyl), -O(C 1-5 alkyl) (e.g., methoxy or ethoxy), -S(C 1-5 alkyl), halogen, C 1-5 haloalkyl (e.g., -CF 3 ), -O-(C 1-5 haloalkyl) (e.g., -OCF 3 ), and -CN. It is particularly preferred that each R 5 is independently a C 1-5 alkyl, particularly methyl.
  • Each R 6 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alky ny I, -(C 0-3 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-O(C 1-5 alkylene)-OH, -(C 0-3 alkylene)-O(C 1-5 alkylene)-O(C 1-5 alkyl), -(C 0-3 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-S(C 1-5 alkylene)-SH, -(C 0-3 alkylene)-S(C 1-5 alkylene)-S(C 1-5 alkyl), -(C 0-3 alkylene)-NH 2 , -(C 0-3 alkylene)-NH(C 1-5 alkyl), -(C
  • each R 6 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -OH, -O(C 1-5 alkyl), -O(C 1-5 alkylene)-OH, -O(C 1-5 alkylene)-O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -S(C 1-5 alkylene)-SH, -S(C 1-5 alkylene)-S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), -NH-OH, -N(C 1-5 alkyl)-OH, -NH-O(C 1-5 alkyl), -N(C 1-5 alkyl)-O(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), halogen,
  • each R 6 is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -O(C 1-5 alkyl), -S(C 1-5 alkyl), -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -(C 0-3 alkylene)-CN, -(C 0-3 alkylene)-carbocyclyl, and -(C 0-3 alkylene)-heterocyclyl, wherein the carbocyclyl group in said -(C 0-3 alkylene)-carbocyclyl and the heterocyclyl group in said -(C 0-3 alky lene)-heterocyclyI are each optionally substituted with one or more groups R Cyc , and further wherein one or two -CH 2 -
  • each R 6 is independently selected from C 1-5 alkyl, -O(C 1-5 alkyl), -S(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -(C 0-3 alkylene)-carbocyclyl, and -(C 0-3 alkylene)-heterocyclyl, wherein the carbocyclyl in said -(C 0-3 alkylene)-carbocyclyl and the heterocyclyl in said -(C 0-3 alky lene)-heterocyclyl are each optionally substituted with one or more groups R Cyc .
  • each R 6 is independently selected from C 1-5 alkyl (e.g., methyl or ethyl), -O(C 1-5 alkyl), -S(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), and -CN.
  • m is an integer of 0 to 4 (i.e., 0, 1, 2, 3 or 4).
  • m is 0, 1 or 2. More preferably, m is 1 or 2. Even more preferably, m is 1.
  • variable m indicates the number of substituents R 5 that are attached to the phenyl ring (which carries the group -SO 2 -NR 3 R 4 ) in the compound of formula (I). If m is 0, then the corresponding phenyl ring is not substituted with any group R 5 , i.e. is substituted with hydrogen instead of R 5 .
  • m ⁇ 1 (e.g., if m is 1 or 2), it is preferred that one group R 5 is attached to the corresponding phenyl ring in para- position with respect to the attachment point of the phthalazine ring. Accordingly, if m is 1, it is preferred that the group R 5 is attached to the corresponding phenyl ring in para-position with respect to the attachment point of the phthalazine ring, as illustrated in the following: In this case, it is particularly preferred that the group R 5 (which is attached to the phenyl ring in para-position with respect to the attachment point of the phthalazine ring, as shown above) is selected from C 1-5 alkyl (e.g., methyl or ethyl), -O(C 1-5 alkyl) (e.g., methoxy or ethoxy), -S(C 1-5 alkyl), halogen, C 1-5 haloalkyl (e.g., -CF 3 ), -O-
  • variable n indicates the number of substituents R 6 that are bound to the phthalazine ring (more specifically to the phenyl moiety which is comprised in the phthalazine ring, i.e., to the phenyl moiety which is fused with a pyridazine moiety to result in the phthalazine ring) in the compound of formula (I). If n is 0, then the phthalazine ring is not substituted with any group R 6 , i.e. is substituted with hydrogen instead of R 6 .
  • Each R Cyc is independently selected from C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, -OH, -O(C 1-5 alkyl), -O(C 1-5 alkylene)- OH, -O(C 1-5 alkylene)-O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -S(C 1-5 alkylene)-SH, -S(C 1-5 alkylene)-S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), -NH-OH, -N(C 1-5 alkyl)-OH, -NH-O(C 1-5 alkyl), -N(C 1-5 alkyl)-O(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -
  • Each L C1 is independently selected from a covalent bond, C 1-5 alkylene, C 2-5 alkenylene, and C 2-5 alky nylene, wherein said alkylene, said alkenylene and said alkynylene are each optionally substituted with one or more (e.g., one, two or three) groups independently selected from halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -OH, -O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -NH2, -NH(C 1-5 alkyl), and -N(C 1-5 alkyl)(C 1-5 alkyl), and further wherein one or more (e.g., one, two or three) -CH 2 - units comprised in said alkylene, said alkenylene or said alkynylene are each optionally replaced by a group independently selected from -O-, -NH-, -N
  • Each R C1 is independently selected from -OH, -O(C 1-5 alkyl), -O(C 1-5 alkylene)-OH, -O(C 1-5 alkylene)-O(C 1-5 alkyl), -SH, -S(C 1-5 alkyl), -S(C 1-5 alkylene)-SH, -S(C 1-5 alkylene)-S(C 1-5 alkyl), -NH 2 , -NH(C 1-5 alkyl), -N(C 1-5 alkyl)(C 1-5 alkyl), -NH-OH, -N(C 1-5 alkyl)-OH, -NH-O(C 1-5 alkyl), -N(C 1-5 alkyl)-O(C 1-5 alkyl), halogen, C 1-5 haloalkyl, -O-(C 1-5 haloalkyl), -CN, -CHO, -CO(C 1-5 alkyl), -COOH, -C
  • X is -N(R 2 )- R 1 , -O-R 1 , -S-R 1 or -CH 2 -R 1 , and if R 3 and R 4 are mutually joined to form, together with the nitrogen atom that they are attached to, a morpholin-4-yl group which is optionally substituted with one or more groups R 32 , then L is not a covalent bond.
  • the compound of formula (I) is any one of the specific compounds described herein below in the examples section, either in non-salt form or as a pharmaceutically acceptable salt of the respective compound.
  • the compound of formula (I) is any one of the following compounds: or a pharmaceutically acceptable salt of any one of the aforementioned compounds.
  • the compound of formula (I) is not 2-methyl-N-(oxolan-2-ylmethyl)-5-[4- (phenylmethylamino)phthalazin-1-yl]benzenesulfonamide or a pharmaceutically acceptable salt thereof. Accordingly, in this embodiment, the compound 2-methyl-N-(oxolan-2-ylmethyl)-5-[4-(phenylmethylamino)phthalazin-1- yljbenzenesulfonamide is excluded from formula (I).
  • the compound of formula (I) is not a compound of the following formula: or a pharmaceutically acceptable salt thereof. Accordingly, in this embodiment, the above-depicted compound is excluded from formula (I).
  • the compounds of formula (I) can be prepared in accordance with, or in analogy to, the synthetic routes described in the following general schemes (abbreviations used - “B 2 pin 2 ": Bis(pinacolato)diboron; “dppf”: 1,1’-bis(diphenylphosphino)ferrocene; “KOAc”: potassium acetate; “Pd(PPh 3 ) 4 ": tetrakis(triphenylphosphine)palladium(0); “DME”: dimethoxyethane): Scheme 1 :
  • hydrocarbon group refers to a group consisting of carbon atoms and hydrogen atoms.
  • alicyclic is used in connection with cyclic groups and denotes that the corresponding cyclic group is non- aromatic.
  • alkyl refers to a monovalent saturated acyclic (i.e., non-cyclic) hydrocarbon group which may be linear or branched. Accordingly, an “alkyl” group does not comprise any carbon-to-carbon double bond or any carbon-to-carbon triple bond.
  • a “C 1-5 alkyl” denotes an alkyl group having 1 to 5 carbon atoms. Preferred exemplary alkyl groups are methyl, ethyl, propyl (e.g., n-propyl or isopropyl), or butyl (e.g., n-butyl, isobutyl, sec-butyl, or tert- butyl).
  • alkyl preferably refers to C1.4 alkyl, more preferably to methyl or ethyl, and even more preferably to methyl.
  • alkenyl refers to a monovalent unsaturated acyclic hydrocarbon group which may be linear or branched and comprises one or more (e.g, one or two) carbon-to-carbon double bonds while it does not comprise any carbon-to-carbon triple bond.
  • C 2-5 alkenyl denotes an alkenyl group having 2 to 5 carbon atoms.
  • Preferred exemplary alkenyl groups are ethenyl, propenyl (e.g., prop-1 -en-1-yl, prop-1 -en-2-yl, or prop-2-en-1-yl), butenyl, butadienyl (e.g., buta-1,3-dien-1-yl or buta-1,3-dien-2-yl), pentenyl, or pentadienyl (e.g., isoprenyl).
  • alkenyl preferably refers to C 2-4 alkenyl.
  • alkynyl refers to a monovalent unsaturated acyclic hydrocarbon group which may be linear or branched and comprises one or more (e.g, one or two) carbon-to-carbon triple bonds and optionally one or more (e.g, one or two) carbon-to-carbon double bonds.
  • C 2-5 alkynyl denotes an alkynyl group having 2 to 5 carbon atoms.
  • Preferred exemplary alkynyl groups are ethynyl, propynyl (e.g, propargyl), or butynyl.
  • alkynyl preferably refers to C 2-4 alkynyl.
  • alkylene refers to an alkanediyl group, i.e. a divalent saturated acyclic hydrocarbon group which may be linear or branched.
  • a “C 1-5 alkylene” denotes an alkylene group having 1 to 5 carbon atoms, and the term “C 0-3 alkylene” indicates that a covalent bond (corresponding to the option “C 0 alkylene”) or a C1.3 alkylene is present.
  • Preferred exemplary alkylene groups are methylene (-CH 2 -), ethylene (e.g., -CH 2 -CH 2 - or -CH(-CH 3 )-), propylene (e.g., -CH 2 -CH 2 -CH 2 -, -CH(-CH 2 -CH 3 )-, -CH 2 -CH(-CH 3 )-, or -CH(-CH 3 )-CH 2 -), or butylene (e.g, -CH 2 -CH 2 - CH 2 -CH 2 -).
  • alkylene preferably refers to C1.4 alkylene (including, in particular, linear C1.4 alkylene), more preferably to methylene or ethylene, and even more preferably to methylene.
  • alkenylene refers to an alkenediyl group, i.e. a divalent unsaturated acyclic hydrocarbon group which may be linear or branched and comprises one or more (e.g, one or two) carbon-to-carbon double bonds while it does not comprise any carbon-to-carbon triple bond.
  • a “C 2-5 alkenylene” denotes an alkenylene group having 2 to 5 carbon atoms.
  • alkenylene preferably refers to C 2-4 alkenylene (including, in particular, linear C 2-4 alkenylene).
  • alkynylene refers to an alkynediyl group, i.e. a divalent unsaturated acyclic hydrocarbon group which may be linear or branched and comprises one or more (e.g, one or two) carbon-to-carbon triple bonds and optionally one or more (e.g, one or two) carbon-to-carbon double bonds.
  • a “C 2-5 alkynylene” denotes an alkynylene group having 2 to 5 carbon atoms.
  • alkynylene preferably refers to C 2-4 alkynylene (including, in particular, linear C 2-4 alkynylene).
  • carbocyclyl refers to a hydrocarbon ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g, of two or three rings), wherein said ring group may be saturated, partially unsaturated (i.e, unsaturated but not aromatic) or aromatic.
  • “carbocyclyl” preferably refers to aryl, cycloalkyl or cycloalkenyl.
  • heterocyclyl refers to a ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g, of two or three rings), wherein said ring group comprises one or more (such as, e.g., one, two, three, or four) ring heteroatoms independently selected from 0, S and N, and the remaining ring atoms are carbon atoms, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) may optionally be oxidized, wherein one or more carbon ring atoms may optionally be oxidized (i.e., to form an oxo group), and further wherein said ring group may be saturated, partially unsaturated (i.e., unsaturated but not aromatic) or aromatic.
  • each heteroatom-containing ring comprised in said ring group may contain one or two 0 atoms and/or one or two S atoms (which may optionally be oxidized) and/or one, two, three or four N atoms (which may optionally be oxidized), provided that the total number of heteroatoms in the corresponding heteroatom-containing ring is 1 to 4 and that there is at least one carbon ring atom (which may optionally be oxidized) in the corresponding heteroatom-containing ring.
  • heterocyclyl preferably refers to heteroaryl, heterocycloalkyl or heterocycloalkenyl.
  • aryl refers to an aromatic hydrocarbon ring group, including monocyclic aromatic rings as well as bridged ring and/or fused ring systems containing at least one aromatic ring (e.g., ring systems composed of two or three fused rings, wherein at least one of these fused rings is aromatic; or bridged ring systems composed of two or three rings, wherein at least one of these bridged rings is aromatic).
  • aryl is a bridged and/or fused ring system which contains, besides one or more aromatic rings, at least one non-aromatic ring (e.g., a saturated ring or an unsaturated alicyclic ring), then one or more carbon ring atoms in each non-aromatic ring may optionally be oxidized (i.e., to form an oxo group).
  • non-aromatic ring e.g., a saturated ring or an unsaturated alicyclic ring
  • carbon ring atoms in each non-aromatic ring may optionally be oxidized (i.e., to form an oxo group).
  • Aryl may, e.g., refer to phenyl, naphthyl, dialinyl (i.e., 1,2-dihydronaphthyl), tetralinyl (i.e., 1,2,3,4-tetrahydronaphthyl), indanyl, indenyl (e.g., 1H-indenyl), anthracenyl, phenanthrenyl, 9H-fluorenyl, or azulenyl.
  • dialinyl i.e., 1,2-dihydronaphthyl
  • tetralinyl i.e., 1,2,3,4-tetrahydronaphthyl
  • indanyl e.g., indenyl (e.g., 1H-indenyl), anthracenyl, phenanthrenyl, 9H-fluorenyl, or azulenyl.
  • an “aryl” preferably has 6 to 14 ring atoms, more preferably 6 to 10 ring atoms, even more preferably refers to phenyl or naphthyl, and most preferably refers to phenyl.
  • heteroaryl refers to an aromatic ring group, including monocyclic aromatic rings as well as bridged ring and/or fused ring systems containing at least one aromatic ring (e.g., ring systems composed of two or three fused rings, wherein at least one of these fused rings is aromatic; or bridged ring systems composed of two or three rings, wherein at least one of these bridged rings is aromatic), wherein said aromatic ring group comprises one or more (such as, e.g., one, two, three, or four) ring heteroatoms independently selected from 0, S and N, and the remaining ring atoms are carbon atoms, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) may optionally be oxidized, and further wherein one or more carbon ring atoms may optionally be oxidized (i.e., to form an oxo group).
  • aromatic ring group comprises one or more (such as, e.g., one, two, three
  • each heteroatom-containing ring comprised in said aromatic ring group may contain one or two 0 atoms and/or one or two S atoms (which may optionally be oxidized) and/or one, two, three or four N atoms (which may optionally be oxidized), provided that the total number of heteroatoms in the corresponding heteroatom-containing ring is 1 to 4 and that there is at least one carbon ring atom (which may optionally be oxidized) in the corresponding heteroatom-containing ring.
  • Heteroaryl may, e.g., refer to thienyl (i.e., thiophenyl), benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl (i.e., furanyl), benzofuranyl, isobenzofuranyl, chromanyl, chromenyl (e.g., 2H-1-benzopyranyl or 4H-1-benzopyranyl), isochromenyl (e.g., 1H-2-benzopyranyl), chromonyl, xanthenyl, phenoxathiinyl, pyrrolyl (e.g., 1H-pyrrolyl), imidazolyl, pyrazolyl, pyridyl (i.e., pyridinyl; e.g., 2-pyridyl, 3-pyridyl, or 4-pyridyl), pyrazin
  • 1,2,4-oxadiazolyl 1,2,5-oxadiazolyl (i.e., furazanyl), or 1,3,4-oxadiazolyl)
  • thiadiazolyl e.g., 1,2,4-thiadiazolyl, 1,2,5- thiadiazolyl, or 1,3,4-thiadiazolyl
  • phenoxazinyl pyrazolo[1,5-a]pyrimidinyl (e.g., pyrazolo[1,5-a]pyrimidin-3-yl), 1,2-benzoisoxazol-3-yl
  • benzothiazolyl benzothiadiazolyl
  • benzoxazolyl benzisoxazolyl
  • benzimidazolyl benzo[b]thiophenyl (i.e., benzothienyl)
  • triazolyl e.g., 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H
  • 1,2,4-triazolyl benzotri azolyl, 1H-tetrazolyl, 2H-tetrazolyl, triazinyl (e.g., 1,2,3-triazinyl, 1,2,4-triazinyl, or 1,3,5- triazinyl), furo[2,3-c]pyridinyl, dihydrofuropyridinyl (e.g., 2,3-dihydrofuro[2,3-c]pyridinyl or 1,3-dihydrofuro[3,4- cjpyridinyl), imidazopyridinyl (e.g., imidazo[1,2-a]pyridinyl or imidazo[3,2-a]pyridinyl), quinazolinyl, thienopyridinyl, tetrahydrothienopyridinyl (e.g., 4,5,6,7-tetrahydrothieno[3,2-c]pyridiny
  • heteroaryl preferably refers to a 5 to 14 membered (more preferably 5 to 10 membered) monocyclic ring or fused ring system comprising one or more (e.g., one, two, three or four) ring heteroatoms independently selected from 0, S and N, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized; even more preferably, a “heteroaryl” refers to a 5 or 6 membered monocyclic ring comprising one or more (e.g., one, two or three) ring heteroatoms independently selected from 0, S and N, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized.
  • heteroaryl examples include pyridinyl (e.g., 2-pyridyl, 3-pyridyl, or 4-pyridyl), imidazolyl, thiazolyl, 1H-tetrazolyl, 2H-tetrazolyl, thienyl (i.e., thiophenyl), or pyrimidinyl.
  • cycloalkyl refers to a saturated hydrocarbon ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g., of two or three rings; such as, e.g., a fused ring system composed of two or three fused rings).
  • Cycloalkyl may, e.g., refer to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, decalinyl (i.e., decahydronaphthyl), or adamantyl.
  • cycloalkyl preferably refers to a C 3-11 cycloalkyl, and more preferably refers to a C 3-7 cycloalkyl.
  • a particularly preferred “cycloalkyl” is a monocyclic saturated hydrocarbon ring having 3 to 7 ring members.
  • particularly preferred examples of a “cycloalkyl” include cyclohexyl or cyclopropyl, particularly cyclohexyl.
  • heterocycloalkyl refers to a saturated ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g., of two or three rings; such as, e.g., a fused ring system composed of two or three fused rings), wherein said ring group contains one or more (such as, e.g., one, two, three, or four) ring heteroatoms independently selected from 0, S and N, and the remaining ring atoms are carbon atoms, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) may optionally be oxidized, and further wherein one or more carbon ring atoms may optionally be oxidized (I.
  • each heteroatom-containing ring comprised in said saturated ring group may contain one or two 0 atoms and/or one or two S atoms (which may optionally be oxidized) and/or one, two, three or four N atoms (which may optionally be oxidized), provided that the total number of heteroatoms in the corresponding heteroatom- containing ring is 1 to 4 and that there is at least one carbon ring atom (which may optionally be oxidized) in the corresponding heteroatom-containing ring.
  • Heterocycloalkyl may, e.g., refer to aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, azepanyl, diazepanyl (e.g., 1,4-diazepanyl), oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, morpholinyl (e.g., morpholin-4-yl), thiomorpholinyl (e.g., thiomorpholin-4- yl), oxazepanyl, oxiranyl, oxetanyl, tetrahydrofuranyl, 1,3-dioxolanyl, tetrahydropyranyl, 1,4-dioxanyl, oxepanyl, thii
  • heterocycloalkyl preferably refers to a 3 to 11 membered saturated ring group, which is a monocyclic ring or a fused ring system (e.g., a fused ring system composed of two fused rings), wherein said ring group contains one or more (e.g., one, two, three, or four) ring heteroatoms independently selected from 0, S and N, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized; more preferably, “heterocycloalkyl” refers to a 5 to 7 membered saturated monocyclic ring group containing one or more (e.g., one, two, or three) ring heteroatoms independently selected from 0, S and N, wherein one or more S ring atoms (if present) and/or one or more N ring atoms
  • heterocycloalkyl examples include tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, or tetrahydrofuranyl.
  • cycloalkenyl refers to an unsaturated alicyclic (non-aromatic) hydrocarbon ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g., of two or three rings; such as, e.g., a fused ring system composed of two or three fused rings), wherein said hydrocarbon ring group comprises one or more (e.g., one or two) carbon-to-carbon double bonds and does not comprise any carbon-to-carbon triple bond.
  • Cycloalkenyl may, e.g., refer to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, or cycloheptadienyl.
  • cycloalkenyl preferably refers to a C 3-11 cycloalkenyl, and more preferably refers to a C 3-7 cycloalkenyl.
  • a particularly preferred “cycloalkenyl” is a monocyclic unsaturated alicyclic hydrocarbon ring having 3 to 7 ring members and containing one or more (e.g., one or two; preferably one) carbon-to-carbon double bonds.
  • heterocycloalkenyl refers to an unsaturated alicyclic (non-aromatic) ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g., of two or three rings; such as, e.g., a fused ring system composed of two or three fused rings), wherein said ring group contains one or more (such as, e.g., one, two, three, or four) ring heteroatoms independently selected from 0, S and N, and the remaining ring atoms are carbon atoms, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) may optionally be oxidized, wherein one or more carbon ring atoms may optionally be oxidized (i.e., to form an oxo group), and further wherein said ring group comprises at least one double bond between adjacent
  • each heteroatom-containing ring comprised in said unsaturated alicyclic ring group may contain one or two 0 atoms and/or one or two S atoms (which may optionally be oxidized) and/or one, two, three or four N atoms (which may optionally be oxidized), provided that the total number of heteroatoms in the corresponding heteroatom-containing ring is 1 to 4 and that there is at least one carbon ring atom (which may optionally be oxidized) in the corresponding heteroatom- containing ring.
  • Heterocycloalkenyl may, e.g., refer to imidazolinyl (e.g., 2-imidazolinyl (i.e., 4,5-dihydro-1H- imidazolyl), 3-imidazolinyl, or 4-imidazolinyl), tetrahydropyridinyl (e.g., 1,2,3,6-tetrahydropyridinyl), dihydropyridinyl (e.g., 1,2-dihydropyridinyl or 2,3-dihydropyridinyl), pyranyl (e.g., 2H-pyranyl or 4H-pyranyl), thiopyranyl (e.g., 2H-thiopyranyl or 4H-thiopyranyl), dihydropyranyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrazinyl, dihydroisoindolyl, oct
  • heterocycloalkenyl preferably refers to a 3 to 11 membered unsaturated alicyclic ring group, which is a monocyclic ring or a fused ring system (e.g., a fused ring system composed of two fused rings), wherein said ring group contains one or more (e.g., one, two, three, or four) ring heteroatoms independently selected from 0, S and N, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) are optionally oxidized, wherein one or more carbon ring atoms are optionally oxidized, and wherein said ring group comprises at least one double bond between adjacent ring atoms and does not comprise any triple bond between adjacent ring atoms; more preferably, “heterocycloalkenyl” refers to a 5 to 7 membered monocyclic unsaturated non-aromatic ring group containing one or more (e.g
  • halogen refers to fluoro (-F), chloro (-CI), bromo (-Br), or iodo (-1).
  • haloalkyl refers to an alkyl group substituted with one or more (preferably 1 to 6, more preferably 1 to 3) halogen atoms which are selected independently from fluoro, chloro, bromo and iodo, and are preferably all fluoro atoms. It will be understood that the maximum number of halogen atoms is limited by the number of available attachment sites and, thus, depends on the number of carbon atoms comprised in the alkyl moiety of the haloalkyl group.
  • Haloalkyl may, e.g., refer to -CF 3 , -CHF 2 , -CH 2 F, -CF 2 -CH 3 , -CH 2 -CF 3 , -CH 2 -CHF 2 , -CH 2 -CF 2 -CH 3 , -CH 2 -CF 2 -CF 3 , or -CH(CF 3 ) 2 .
  • a particularly preferred “haloalkyl” group is -CF 3 .
  • the terms “optional”, “optionally” and “may” denote that the indicated feature may be present but can also be absent.
  • the present invention specifically relates to both possibilities, i.e., that the corresponding feature is present or, alternatively, that the corresponding feature is absent.
  • the expression “X is optionally substituted with Y” (or “X may be substituted with Y”) means that X is either substituted with Y or is unsubstituted.
  • a component of a composition is indicated to be “optional”, the invention specifically relates to both possibilities, i.e., that the corresponding component is present (contained in the composition) or that the corresponding component is absent from the composition.
  • substituents such as, e.g., one, two, three or four substituents. It will be understood that the maximum number of substituents is limited by the number of attachment sites available on the substituted moiety.
  • the “optionally substituted” groups referred to in this specification carry preferably not more than two substituents and may, in particular, carry only one substituent.
  • the optional substituents are absent, i.e. that the corresponding groups are unsubstituted.
  • substituent groups comprised in the compounds of the present invention may be attached to the remainder of the respective compound via a number of different positions of the corresponding specific substituent group. Unless defined otherwise, the preferred attachment positions for the various specific substituent groups are as illustrated in the examples.
  • compositions comprising “a” compound of formula (I) can be interpreted as referring to a composition comprising “one or more” compounds of formula (I).
  • the term “comprising” (or “comprise”, “comprises”, “contain”, “contains”, or “containing”), unless explicitly indicated otherwise or contradicted by context, has the meaning of “containing, inter alia”, i.e., “containing, among further optional elements, ...”. In addition, this term also includes the narrower meanings of “consisting essentially of and “consisting of.
  • a comprising B and C has the meaning of “A containing, inter alia, B and C”, wherein A may contain further optional elements (e.g., “A containing B, C and D” would also be encompassed), but this term also includes the meaning of “A consisting essentially of B and C” and the meaning of “A consisting of B and C” (i.e., no other components than B and C are comprised in A).
  • the scope of the invention embraces all pharmaceutically acceptable salt forms of the compounds of formula (I) which may be formed, e.g., by protonation of an atom carrying an electron lone pair which is susceptible to protonation, such as an amino group, with an inorganic or organic acid, or as a salt of an acid group (such as a carboxylic acid group) with a physiologically acceptable cation.
  • Exemplary base addition salts comprise, for example: alkali metal salts such as sodium or potassium salts; alkaline earth metal salts such as calcium or magnesium salts; zinc salts; ammonium salts; aliphatic amine salts such as trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, procaine salts, meglumine salts, ethylenediamine salts, or choline salts; aralkyl amine salts such as N,N-dibenzylethylenediamine salts, benzathine salts, benethamine salts; heterocyclic aromatic amine salts such as pyridine salts, picoline salts, quinoline salts or isoquinoline salts; quaternary ammonium salts such as tetramethylammonium salts, tetraethylammonium salts, benzyltrimethylammonium salts, benzyltriethylam
  • Exemplary acid addition salts comprise, for example: mineral acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate salts (such as, e.g., sulfate or hydrogensulfate salts), nitrate salts, phosphate salts (such as, e.g., phosphate, hydrogenphosphate, or dihydrogenphosphate salts), carbonate salts, hydrogencarbonate salts, perchlorate salts, borate salts, or thiocyanate salts; organic acid salts such as acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, octanoate, cyclopentanepropionate, decanoate, undecanoate, oleate, stearate, lactate, maleate, oxalate, fumarate, tartrate, malate, citrate, succinate, adipate, gluconate, glycolate, nic
  • Preferred pharmaceutically acceptable salts of the compounds of formula (I) include a hydrochloride salt, a hydrobromide salt, a mesylate salt, a sulfate salt, a tartrate salt, a fumarate salt, an acetate salt, a citrate salt, and a phosphate salt.
  • a particularly preferred pharmaceutically acceptable salt of the compound of formula (I) is a hydrochloride salt.
  • the present invention also specifically relates to the compound of formula (I), including any one of the specific compounds of formula (I) described herein, in non-salt form.
  • the scope of the invention embraces the compounds of formula (I) in any solvated form, including, e.g., solvates with water (i.e., as a hydrate) or solvates with organic solvents such as, e.g., methanol, ethanol, isopropanol, acetic acid, ethyl acetate, ethanolamine, DMSO, or acetonitrile. All physical forms, including any amorphous or crystalline forms (i.e., polymorphs), of the compounds of formula (I) are also encompassed within the scope of the invention. It is to be understood that such solvates and physical forms of pharmaceutically acceptable salts of the compounds of the formula (I) are likewise embraced by the invention.
  • the compounds of formula (I) may exist in the form of different isomers, in particular stereoisomers (including, e.g., geometric isomers (or cis/trans isomers), enantiomers and diastereomers) or tautomers (including, in particular, prototropic tautomers, such as keto/enol tautomers). All such isomers of the compounds of formula (I) are contemplated as being part of the present invention, either in admixture or in pure or substantially pure form.
  • stereoisomers the invention embraces the isolated optical isomers of the compounds according to the invention as well as any mixtures thereof (including, in particular, racemic mixtures/racemates).
  • the racemates can be resolved by physical methods, such as, e.g., fractional crystallization, separation or crystallization of diastereomeric derivatives, or separation by chiral column chromatography.
  • the individual optical isomers can also be obtained from the racemates via salt formation with an optically active acid followed by crystallization.
  • the present invention further encompasses any tautomers of the compounds of formula (I). It will be understood that some compounds may exhibit tautomerism. In such cases, the formulae provided herein expressly depict only one of the possible tautomeric forms.
  • the formulae and chemical names as provided herein are intended to encompass any tautomeric form of the corresponding compound and not to be limited merely to the specific tautomeric form depicted by the drawing or identified by the name of the compound.
  • the scope of the invention also embraces compounds of formula (I), in which one or more atoms are replaced by a specific isotope of the corresponding atom.
  • the invention encompasses compounds of formula (I), in which one or more hydrogen atoms (or, e.g., all hydrogen atoms) are replaced by deuterium atoms (i.e., 2 H; also referred to as “D”).
  • the invention also embraces compounds of formula (I) which are enriched in deuterium.
  • Naturally occurring hydrogen is an isotopic mixture comprising about 99.98 mol-% hydrogen-1 ( 1 H) and about 0.0156 mol-% deuterium ( 2 H or D).
  • the content of deuterium in one or more hydrogen positions in the compounds of formula (I) can be increased using deuteration techniques known in the art.
  • a compound of formula (I) or a reactant or precursor to be used in the synthesis of the compound of formula (I) can be subjected to an H/D exchange reaction using, e.g., heavy water (D2O).
  • D2O heavy water
  • deuteration techniques are described in: Atzrodt J et al., Bioorg Med Chem, 2012, 20(18):5658-5667; William JS et al., Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53(11-12):635-644; Modvig Aet al., JOrg Chem, 2014, 79:5861-5868.
  • the content of deuterium can be determined, e.g., using mass spectrometry or NMR spectroscopy.
  • it is preferred that the compound of formula (I) is not enriched in deuterium. Accordingly, the presence of naturally occurring hydrogen atoms or 1 H hydrogen atoms in the compounds of formula (I) is preferred.
  • the present invention also embraces compounds of formula (I), in which one or more atoms are replaced by a positron-emitting isotope of the corresponding atom, such as, e.g., 18 F, 11 C, 13 N, 15 O, 76 Br, 77 Br, 120 l and/or 124 l.
  • a positron-emitting isotope of the corresponding atom such as, e.g., 18 F, 11 C, 13 N, 15 O, 76 Br, 77 Br, 120 l and/or 124 l.
  • Such compounds can be used as tracers, trackers or imaging probes in positron emission tomography (PET).
  • the invention thus includes (i) compounds of formula (I), in which one or more fluorine atoms (or, e.g., all fluorine atoms) are replaced by 18 F atoms, (ii) compounds of formula (I), in which one or more carbon atoms (or, e.g., all carbon atoms) are replaced by 11 C atoms, (ill) compounds of formula (I), in which one or more nitrogen atoms (or, e.g., all nitrogen atoms) are replaced by 13 N atoms, (iv) compounds of formula (I), in which one or more oxygen atoms (or, e.g., all oxygen atoms) are replaced by 15 O atoms, (v) compounds of formula (I), in which one or more bromine atoms (or, e.g., all bromine atoms) are replaced by 76 Br atoms, (vi) compounds of formula (I), in which one or more bromine atoms (or, e.g., all bromine
  • the compounds provided herein may be administered as compounds perse or may be formulated as medicaments.
  • the medicaments/pharmaceutical compositions may optionally comprise one or more pharmaceutically acceptable excipients, such as carriers, diluents, fillers, disintegrants, lubricating agents, binders, colorants, pigments, stabilizers, preservatives, antioxidants, and/or solubility enhancers.
  • the pharmaceutical compositions may comprise one or more solubility enhancers, such as, e.g., polyethylene glycol), including poly (ethylene glycol) having a molecular weight in the range of about 200 to about 5,000 Da (e.g., PEG 200, PEG 300, PEG 400, or PEG 600), ethylene glycol, propylene glycol, glycerol, a non-ionic surfactant, tyloxapol, polysorbate 80, macrogol-15-hydroxystearate (e.g., Kolliphor® MS 15, CAS 70142-34-6), a phospholipid, lecithin, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, a cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, hydroxyethyl- ⁇ -cyclodextrin,
  • solubility enhancers such as
  • the pharmaceutical compositions may also comprise one or more preservatives, particularly one or more antimicrobial preservatives, such as, e.g., benzyl alcohol, chlorobutanol, 2-ethoxyethanol, m-cresol, chlorocresol (e.g., 2-chloro-3-methyl-phenol or 4-chloro-3-methyl-phenol), benzalkonium chloride, benzethonium chloride, benzoic acid (or a pharmaceutically acceptable salt thereof), sorbic acid (or a pharmaceutically acceptable salt thereof), chlorhexidine, thimerosal, or any combination thereof.
  • preservatives particularly one or more antimicrobial preservatives, such as, e.g., benzyl alcohol, chlorobutanol, 2-ethoxyethanol, m-cresol, chlorocresol (e.g., 2-chloro-3-methyl-phenol or 4-chloro-3-methyl-phenol), benzalkonium chloride, benzethonium chloride, benzoic
  • compositions can be formulated by techniques known to the person skilled in the art, such as the techniques published in “Remington: The Science and Practice of Pharmacy”, Pharmaceutical Press, 22 nd edition.
  • the pharmaceutical compositions can be formulated as dosage forms for oral, parenteral, such as intramuscular, intravenous, subcutaneous, intradermal, intraarterial, intracardial, rectal, nasal, topical, aerosol or vaginal administration.
  • Dosage forms for oral administration include coated and uncoated tablets, soft gelatin capsules, hard gelatin capsules, lozenges, troches, solutions, emulsions, suspensions, syrups, elixirs, powders and granules for reconstitution, dispersible powders and granules, medicated gums, chewing tablets and effervescent tablets.
  • Dosage forms for parenteral administration include solutions, emulsions, suspensions, dispersions and powders and granules for reconstitution. Emulsions are a preferred dosage form for parenteral administration.
  • Dosage forms for rectal and vaginal administration include suppositories and ovula.
  • Dosage forms for nasal administration can be administered via inhalation and insufflation, for example by a metered inhaler.
  • Dosage forms for topical administration include creams, gels, ointments, salves, patches and transdermal delivery systems.
  • the compounds of formula (I) or the above described pharmaceutical compositions comprising a compound of formula (I) may be administered to a subject by any convenient route of administration, whether systemically/peripherally or at the site of desired action, including but not limited to one or more of: oral (e.g., as a tablet, capsule, or as an ingestible solution), topical (e.g., transdermal, intranasal, ocular, buccal, and sublingual), parenteral (e.g., using injection techniques or infusion techniques, and including, for example, by injection, e.g., subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, or intrasternal by, e.g., implant of a depot, for example, subcutaneously or intramuscularly), pulmonary (e
  • examples of such administration include one or more of: intravenously, intraarterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracardially, intracranially, intramuscularly or subcutaneously administering the compounds or pharmaceutical compositions, and/or by using infusion techniques.
  • parenteral administration the compounds are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
  • the aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary.
  • the preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
  • Said compounds or pharmaceutical compositions can also be administered orally in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavoring or coloring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
  • the tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycolate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included. Solid compositions of a similar type may also be employed as fillers in gelatin capsules.
  • excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine
  • disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glyco
  • Preferred excipients in this regard include lactose, starch, a cellulose, or high molecular weight polyethylene glycols.
  • the agent may be combined with various sweetening or flavoring agents, coloring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
  • the compounds or pharmaceutical compositions are preferably administered by oral ingestion, particularly by swallowing.
  • the compounds or pharmaceutical compositions can thus be administered to pass through the mouth into the gastrointestinal tract, which can also be referred to as “oral-gastrointestinal” administration.
  • said compounds or pharmaceutical compositions can be administered in the form of a suppository or pessary, or may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder.
  • the compounds of the present invention may also be dermally or transdermally administered, for example, by the use of a skin patch.
  • sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.
  • Sustained-release matrices include, e.g., polylactides, copolymers of L-glutamic acid and gamma-ethyl-L-glutamate, poly(2-hydroxyethyl methacrylate), ethylene vinyl acetate, or poly-D-(— )-3- hydroxybutyric acid.
  • Sustained-release pharmaceutical compositions also include I iposomally entrapped compounds. The present invention thus also relates to liposomes containing a compound of the invention.
  • Said compounds or pharmaceutical compositions may also be administered by the pulmonary route, rectal routes, or the ocular route.
  • they can be formulated as micronized suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzalkonium chloride.
  • a preservative such as a benzalkonium chloride.
  • they may be formulated in an ointment such as petrolatum. It is also envisaged to prepare dry powder formulations of the compounds of formula (I) for pulmonary administration, particularly inhalation.
  • dry powders may be prepared by spray drying under conditions which result in a substantially amorphous glassy or a substantially crystalline bioactive powder. Accordingly, dry powders of the compounds of the present invention can be made according to an emulsification/spray drying process.
  • said compounds or pharmaceutical compositions can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, emulsifying wax and water.
  • they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, 2-octyldodecanol, benzyl alcohol and water.
  • the present invention thus relates to the compounds or the pharmaceutical compositions provided herein, wherein the corresponding compound or pharmaceutical composition is to be administered by any one of: an oral route; topical route, including by transdermal, intranasal, ocular, buccal, or sublingual route; parenteral route using injection techniques or infusion techniques, including by subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, intrasternal, intraventricular, intraurethral, or intracranial route; pulmonary route, including by inhalation or insufflation therapy; gastrointestinal route; intrauterine route; intraocular route; subcutaneous route; ophthalmic route, including by intravitreal, or intracameral route; rectal route; or vaginal route.
  • Particularly preferred routes of administration are oral administration or parenteral administration.
  • a physician will determine the actual dosage which will be most suitable for an individual subject.
  • the specific dose level and frequency of dosage for any particular individual subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual subject undergoing therapy.
  • the precise dose and also the route of administration will ultimately be at the discretion of the attendant physician or veterinarian.
  • the compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) can be administered in monotherapy (e.g., without concomitantly administering any further therapeutic agents, or without concomitantly administering any further therapeutic agents against the same disease that is to be treated or prevented with the compound of formula (I)).
  • the compounds of formula (I) can be used in the monotherapeutic treatment or prevention of cancer (i.e., without administering any other anticancer agents until the treatment with the compound(s) of formula (I) is terminated).
  • the invention also relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the aforementioned entities in combination with a pharmaceutically acceptable excipient, for use in the monotherapeutic treatment or prevention of cancer.
  • the subject or patient to be treated in accordance with the present invention may be an animal (e.g., a non-human animal).
  • the subject/patient is a mammal.
  • the subject/patient is a human (e.g., a male human or a female human) or a non-human mammal (such as, e.g., a guinea pig, a hamster, a rat, a mouse, a rabbit, a dog, a cat, a horse, a monkey, an ape, a marmoset, a baboon, a gorilla, a chimpanzee, an orangutan, a gibbon, a sheep, cattle, or a pig).
  • a human e.g., a male human or a female human
  • a non-human mammal such as, e.g., a guinea pig, a hamster, a rat, a mouse, a rabbit, a dog, a cat, a horse, a monkey, an ape, a marmoset, a baboon, a gorilla, a chimpan
  • Treatment of a disorder or disease, as used herein, is well known in the art.
  • Treatment of a disorder or disease implies that a disorder or disease is suspected or has been diagnosed in a patient/subject.
  • a patient/subject suspected of suffering from a disorder or disease typically shows specific clinical and/or pathological symptoms which a skilled person can easily attribute to a specific pathological condition (i.e. , diagnose a disorder or disease).
  • the “treatment” of a disorder or disease may, for example, lead to a halt in the progression of the disorder or disease (e.g., no deterioration of symptoms) or a delay in the progression of the disorder or disease (in case the halt in progression is of a transient nature only).
  • the “treatment” of a disorder or disease may also lead to a partial response (e.g., amelioration of symptoms) or complete response (e.g., disappearance of symptoms) of the subject/patient suffering from the disorder or disease.
  • the “treatment” of a disorder or disease may also refer to an amelioration of the disorder or disease, which may, e.g., lead to a halt in the progression of the disorder or disease or a delay in the progression of the disorder or disease.
  • Such a partial or complete response may be followed by a relapse.
  • a subject/patient may experience a broad range of responses to a treatment (such as the exemplary responses as described herein above).
  • the treatment of a disorder or disease may, inter alia, comprise curative treatment (preferably leading to a complete response and eventually to healing of the disorder or disease) and palliative treatment (including symptomatic relief).
  • prevention of a disorder or disease is also well known in the art.
  • a patient/subject suspected of being prone to suffer from a disorder or disease may particularly benefit from a prevention of the disorder or disease.
  • the subject/patient may have a susceptibility or predisposition for a disorder or disease, including but not limited to hereditary predisposition.
  • Such a predisposition can be determined by standard methods or assays, using, e.g., genetic markers or phenotypic indicators.
  • a disorder or disease to be prevented in accordance with the present invention has not been diagnosed or cannot be diagnosed in the patient/subject (for example, the patient/subject does not show any clinical or pathological symptoms).
  • the term “prevention” comprises the use of a compound of the present invention before any clinical and/or pathological symptoms are diagnosed or determined or can be diagnosed or determined by the attending physician.
  • the present invention specifically relates to each and every combination of features and embodiments described herein, including any combination of general and/or preferred features/embodiments.
  • the invention specifically relates to each combination of meanings (including general and/or preferred meanings) for the various groups and variables comprised in formula (I).
  • a number of documents, including patent applications and scientific literature are cited. The disclosure of these documents, while not considered relevant for the patentability of this invention, is herewith incorporated by reference in its entirety. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.
  • FIG. 1 HAP1 assay system. HAP1 cells are sensitive to SLC16A1 (A) inhibition upon SLC16A3 knock-out (KO), and this effect is rescued by re-introduction of wt SLC16A3 cDNA. Similarly, HAP1 SLC16A1 KO cells are sensitive to SLC16A3 inhibition (B). This effect can be disrupted by overexpression of SLC16A7 or SLC16A8 (C), which results in dependency on newly introduced SLC. See Example 1.
  • Figure 2 Selectivity counter screen. Presented compounds selectively kill only cells dependent on SLC16A3 in HAP1 and LAMA84 cell lines. The killing effect is rescued by re-introduction of SLC16A1 WT cDNA but not by SLC16A1 R313Q cDNA, demonstrating that the effect is dependent on the transport function of the SLC. Compound 2 is given as an illustrative example.
  • Figure 3 Secondary assays confirmed SLC16A3 inhibition. Binding of the representative compound 2 was confirmed with CETSA (A). Incubation of SLC16A1 -/- cells with compound 2 for 6 hours resulted in lactate accumulation comparable to control (syrosingopine), while no accumulation was observed in SLC16A3 -/- cells, confirming selectivity (B). Incubation of 2 lung cancer cell lines known for high expression of SLC16A3 with compound 1 for 6 hours resulted in lactate accumulation, validating the findings in HAP1 KO system in additional models (C). See Example 1.
  • Figure 4 Growth reducing effect of the SLC16A3 inhibitors.
  • HAP1, HAP1 SLC16A1 -/- and HAP1 SLC16A3 -/- were obtained from Haplogen. All HAP1 cell lines were grown in IMDM supplemented with 10% FBS and 1% penicillin-streptomycin. LAMA84 sgRen , LAMA84 sgSLC16A1 and LAMA84 sgSLC16A3 were generated previously (Pemovska et al., 2020, submitted to Nature Communications) and were grown in RPMI supplemented with 10% FBS and 1% penicillin-streptomycin. HEK293T cells were obtained from ATCC and cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. NCIH441 and NCIH358 were obtained from laboratory of Georg Winter (CeMM Research Center for Molecular Medicine, Vienna, Austria) and cultured in RPMI supplemented with 10% FBS and 1% penicillin-streptomycin.
  • Codon optimized cDNAs encoding SLC16A1, SLC16A3, SLC16A7 and SLC16A8 in pDONR221 were obtained from RESOLUTE consortium.
  • HIBIT tagging for CETSA experiments was performed on N-termini of SLCs.
  • HIBIT tag and mutations in SLC16A1 and SLC16A3 were introduced in pDONR vectors using site-directed mutagenesis (NEB).
  • cDNAs were then transferred into LEgwSHIB (pRRL-EF1a-gwSH-IRES-BlastR) or LEgwSTOPIB (pRRL-gwSTOP-IRES- BlastR) vectors (Bigenddling JW et al., Science, 2018, 8210(November):eaap8210) using gateway cloning LR reaction (Invitrogen).
  • gRNA CACCGACAGACGTATAGTTGCTGTA
  • All sequences were confirmed by Sanger sequencing.
  • Lentivirus was produced in HEK293T cells transiently co-transfected with psPAX2, pMD2.G and corresponding expression vector. 12 hours after transfection media was changed for collection of lentiviruses. After another 48-72 hours, media containing lentivirus was collected, filtered through 0.2 pm filter and either mixed with 5 pg/ml Polyberene (Hexadimethrine bromide, Sigma) and added to target cells, or stored at -80°C. 24 hours after transduction, virus containing medium was removed and replaced with fresh medium, and in additional 24 hours respective selection antibiotics (puromycin or blasticidin) were added to derive stably expressing cell lines.
  • HAP1 cells were seeded using a dispenser (Thermo Fischer Scientific) in density 1,000 cells per well in 50 pl.
  • DMSO or Bortezomib treatment were used as controls. Viability of cells was assessed after 72 hours with CellTiter Gio (Promega) and % of controls were calculated based on RLU values in DMSO (100%) and Bortezomib (0%) wells.
  • First screening was performed in 10 ⁇ M final concentration.
  • Second screening was performed in technical duplicates, in 4 point dose response setting, with concentrations ranging from 13-0.5 ⁇ M.
  • HEK293T cells with stable expression of HIBIT-tagged SLC16A3 were lysed as described in Hashimoto M et al., ACS Chemical Biology, 2018, 13(6): 1480-86. Lysates were then centrifugated at 14,000 RPM, 20 min at 4°C. Supernatant were next incubated with tested compounds or DMSO on ice for 1 hour. After that samples were aliquoted to PCR strips, heated in gradient thermocycler for 6 min and let cool down at room temperature (RT) for 3 min. Samples were then centrifugated at 14,000 RPM, 40 min at 4°C and protein abundance in supernatants was determined using HIBIT lytic detection system (Promega) in 384 well plate. Reagents for HIBIT detection were diluted in lysis buffer (Hashimoto M et al., loc. cit.) instead of buffer provided with kit. All measurements were done in technical triplicate.
  • Protocol for lactate gio was modified based on Benjamin D et al., Cell Reports, 2018, 25(11):3047-3058.e4.
  • Cells were seeded in 96 well plate in density 30,000 cells per well.
  • Next day cells were treated with tested compounds, AZD3965 and syrosingopine (all in final concentration of 10 ⁇ M) or DMSO.
  • After 6 hours of incubation at 37°C cells were washed twice with PBS, lysed with 0.2N NCI, neutralized with 1M Tris-base (Sigma) and incubated for 1 hour at RT with lactate glo reagents (Promega). Lactate accumulation was then estimated based on luminescence signal.
  • Cells were seeded in 6 well plate in density of 15,000 cells per well in the presence of different concentrations of tested compounds in DMSO, or matching DMSO concentrations. Cells were washed with PBS, harvested with trypsin and counted with CASY counter (Roche) 24h, 48h and 72h after the seeding. Cell number obtained at 24h was set as 0, for each time point and concentration two wells were harvested and counted.
  • HAP1 cells express both SLC16A1 and SLC16A3, and inhibition of either SLC16A1 or SLC16A3 is affecting viability minimally.
  • the inhibition of SLC16A1 in HAP1 SLC16A3 -/- cells leads to severe reduction in fitness.
  • HAP1 cells express none, or very low levels of SLC16A7 and SLC16A8 (Brockmann M et al., Nature, 2017, 546(7657):307—11), and thus the inventors hypothesized that exogenous expression of SLC16A7 or SLC16A8 will disrupt synthetic lethality between SLC16A1 and SLC16A3.
  • the inventors overexpressed SLC16A7 or SLC16A8 in HAP1 SLC16A3 -/- cells and knocked out SLC16A1 using CRISPR/Cas9. They found that cells remain viable, indicating that the exogenous expression of SLC16A7 or SLC16A8 can rescue synthetic lethality.
  • the inventors performed a chemical screening using HAP1 SLC16A1 -/- cells exploiting their dependency on SLC16A3 and the expected reduction in their viability resulting from SLC16A3 inhibition. They obtained >1,400 compounds which reduced viability of cells to ⁇ 50% compared to controls, which were tested further.
  • HAP1 WT HAP1 SLC16A1 -/- and HAP1 SLC16A3 -/- cell lines in 4 different concentration. They identified compounds which were toxic only to SLC16A1 -/- cells, indicating that the target of these compounds has a genetic interaction with SLC16A1. Interestingly, among these hits were compounds sharing a common phtalazine scaffold (Table 1).
  • the inventors created a selection of compounds with similar structure to their hits from the whole library and tested those further. They used a broader panel of cell lines, which included HAP1 WT, HAP1 SLC16A1 -/- , HAP1 SLC16A3 -/ ,- LAMA84 sgRen , LAMA84 sgSLC16A1 and LAMA84 sgSLC16A3 (see Figure 2 with compound 2 as a representative example).
  • HAP1 cell lines with dependency on SLC16A7 and SLC16A8 included HAP1 SLC16A1 -/- , SLC16A1 WT OE; HAP1 SLC16A1 -/- , SLC16A1 R313Q OE; HAP1 SLC16A3 -/ ,- SLC16A3 WT OE and HAP1.
  • the inventors were able to confirm that a range of tested compounds killed HAP1 SLC16A1 -/- ; LAMA84 sgSLC16A1 but not HAP1 WT, HAP1 SLC16A3 -/- , LAMA84 sgRen , LAMA84 sgSLC16A3 or HAP1 with dependency on either SLC16A7 or SLC16A8, indicating specificity to SLC16A3 over SLC16A1, SLC16A7 and SLC16A8.
  • HAP1 SLC16A1 -/- , HAP1 SLC16A3 -/- and HAP1 WT cells are summarized in the following Table 1 (4 point dose response, 0.5 - 13 ⁇ M, technical duplicate) and Tables 2 and 3 (6 point dose response, 0.11 - 27 ⁇ M, technical triplicate):
  • HAP1 WT, HAP1 SLC16A1 -/- or HAP1 SLC16A3 -/- cell lines were treated with presented compounds for 72 hours and viability was determined by Cell titer glo assay (Promega). Data are presented as area under the dose response curve (AUC) values.
  • HAP1 WT, HAP1 SLC16A1 -/- or HAP1 SLC16A3 -/- cell lines were treated with presented compounds for 72 hours and viability was determined by Cell titer glo assay (Promega). Data are presented as area under the dose response curve (AUC) values.
  • the inventors picked compounds 1 and 2 as representative examples. First, they performed Cellular Thermal Shift Assay (CETSA) on SLC16A3 with HEK293T cells stably expressing HIBIT-tagged SLC16A3 employing split-nano luciferase as a readout. Treatment with compound 2 showed a shift in melting temperature of SLC16A3 indicating that this compound is binding SLC16A3 (see Figure 3A). Second, to confirm a direct inhibition of lactate export, the inventors measured lactate accumulation in HAP1 SLC16A1 -/- and HAP1 SLC16A3 -/- cells with Lactate Glo assay upon treatment with compound 2.
  • CETSA Cellular Thermal Shift Assay
  • AU-565 cells were obtained from ATCC and seeded in 96-well plates (Tecan Microplates, cat. #30122306), in density of 500 cells per well. 24 hours after seeding, cells were treated with tested compounds (all in final concentration of 10 mM) or DMSO. Viability was measured after six days using the CellTiter-Glo assay (Promega, cat. #G7572) on a plate reader (Tecan SPARK, cat. #2002005429). All measurements were done in technical triplicates. Data were normalized to DMSO treated-controls using R v4.1.3.
  • Table 4 Viability of AU-565 cancer cells upon treatment with selected compounds. Compounds were tested at a concentration of 10mM and cellular viability measured after 6 days of treatment. Average residual viability compared to DMSO treatment from three technical replicates is reported.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés à base de 3-(phtalazin-1-yl)benzènesulfonamide de formule (I), formule (I) ainsi que des sels pharmaceutiquement acceptables de ceux-ci, qui se sont avérés être avantageusement des inhibiteurs puissants et sélectifs de SLC16A3, ainsi que leur utilisation dans le traitement ou la prévention de maladies/troubles associés à SLC16A3 tels que le cancer.
PCT/EP2022/063944 2021-05-21 2022-05-23 Inhibiteurs de slc16a3 à base de 3-(phtalazin-1-yl) benzènesulfonamide et leur utilisation thérapeutique WO2022243574A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21175426.2 2021-05-21
EP21175426 2021-05-21

Publications (1)

Publication Number Publication Date
WO2022243574A1 true WO2022243574A1 (fr) 2022-11-24

Family

ID=76059822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/063944 WO2022243574A1 (fr) 2021-05-21 2022-05-23 Inhibiteurs de slc16a3 à base de 3-(phtalazin-1-yl) benzènesulfonamide et leur utilisation thérapeutique

Country Status (1)

Country Link
WO (1) WO2022243574A1 (fr)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033288A2 (fr) * 2003-09-29 2005-04-14 The Johns Hopkins University Antagonistes de la voie hedgehog
FR2962649A1 (fr) 2010-07-19 2012-01-20 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
WO2016081464A1 (fr) 2014-11-17 2016-05-26 Nirogyone Therapeutics, Inc. Modulateurs de transport des monocarboxylates et leurs utilisations
WO2016201426A1 (fr) * 2015-06-12 2016-12-15 Vettore, LLC Inhibiteurs de mct4 pour le traitement de maladies
WO2017196936A1 (fr) 2016-05-12 2017-11-16 Regents Of The University Of Minnesota Composés indole et indazole cyanocinnamate et leurs utilisations thérapeutiques
KR20180032707A (ko) * 2016-09-22 2018-04-02 경북대학교 산학협력단 인테그린 억제제를 포함하는 염증성 질환의 예방 및 치료용 약학적 조성물
WO2018111904A1 (fr) 2016-12-12 2018-06-21 Vettore, LLC Inhibiteurs hétérocycliques de mct4
CA2984073A1 (fr) * 2017-10-27 2019-04-27 Nuchem Therapeutics Inc. Inhibiteurs de poles d'arn associes a des polynucleotides repetes et utilisations associees
WO2019104199A1 (fr) 2017-11-21 2019-05-31 Regen Biopharma Inc. Agonistes et antagonistes à petites molécules de l'activité de nr2f6
WO2019215316A1 (fr) 2018-05-11 2019-11-14 Astrazeneca Ab Composés de triazolopyrimidine et leur utilisation dans le traitement du cancer
US20190352282A1 (en) 2018-04-25 2019-11-21 Charles R. Drew University Of Medicine And Science Novel mct4 inhibitors and uses thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033288A2 (fr) * 2003-09-29 2005-04-14 The Johns Hopkins University Antagonistes de la voie hedgehog
FR2962649A1 (fr) 2010-07-19 2012-01-20 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
US20130123266A1 (en) 2010-07-19 2013-05-16 Vax-Consulting Treatment of a pathology linked to an excessive effect of tnf with a benzene sulphonamide compound
WO2016081464A1 (fr) 2014-11-17 2016-05-26 Nirogyone Therapeutics, Inc. Modulateurs de transport des monocarboxylates et leurs utilisations
WO2016201426A1 (fr) * 2015-06-12 2016-12-15 Vettore, LLC Inhibiteurs de mct4 pour le traitement de maladies
WO2017196936A1 (fr) 2016-05-12 2017-11-16 Regents Of The University Of Minnesota Composés indole et indazole cyanocinnamate et leurs utilisations thérapeutiques
KR20180032707A (ko) * 2016-09-22 2018-04-02 경북대학교 산학협력단 인테그린 억제제를 포함하는 염증성 질환의 예방 및 치료용 약학적 조성물
WO2018111904A1 (fr) 2016-12-12 2018-06-21 Vettore, LLC Inhibiteurs hétérocycliques de mct4
CA2984073A1 (fr) * 2017-10-27 2019-04-27 Nuchem Therapeutics Inc. Inhibiteurs de poles d'arn associes a des polynucleotides repetes et utilisations associees
WO2019104199A1 (fr) 2017-11-21 2019-05-31 Regen Biopharma Inc. Agonistes et antagonistes à petites molécules de l'activité de nr2f6
US20190352282A1 (en) 2018-04-25 2019-11-21 Charles R. Drew University Of Medicine And Science Novel mct4 inhibitors and uses thereof
WO2019215316A1 (fr) 2018-05-11 2019-11-14 Astrazeneca Ab Composés de triazolopyrimidine et leur utilisation dans le traitement du cancer

Non-Patent Citations (52)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH
APICELLA M ET AL., CELL METABOLISM, vol. 28, no. 6, 2018, pages 848 - 865
ATZRODT J ET AL., BIOORG MED CHEM, vol. 20, no. 18, 2012, pages 5658 - 5667
BAEK GH ET AL., CELL REPORTS, vol. 9, no. 6, 2014, pages 2233 - 49
BAENKE F ET AL., JOURNAL OF PATHOLOGY, vol. 237, no. 2, 2015, pages 152 - 165
BASSE N ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 1, 2010, pages 509 - 13
BASSE NICOLAS ET AL: "Novel Organic Proteasome Inhibitors Identified by Virtual and in Vitro Screening", vol. 53, no. 1, 14 January 2010 (2010-01-14), US, pages 509 - 513, XP055791026, ISSN: 0022-2623, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/jm9011092> DOI: 10.1021/jm9011092 *
BENJAMIN D ET AL., CELL REPORTS, vol. 25, no. 11, 2018, pages 3047 - 3058
BIGENZAHN JW ET AL., SCIENCE, vol. 8210, 2018, pages eaap8210
BONGLACK EN ET AL., BIORXIV, vol. 12, no. 04, 2020, pages 410563
BOSSHART PD ET AL., TRENDS IN BIOCHEMICAL SCIENCES, 2020, pages 1 - 13
BROCKMANN M ET AL., NATURE, vol. 546, no. 7657, 2017, pages 307 - 11
CAS , no. 70142-34-6
CLUNTUN AA ET AL., CELL METABOLISM, 20 January 2020 (2020-01-20)
CLUNTUN AA ET AL., CELL METABOLISM, 2020, pages 1 - 20
CLUNTUN AA ET AL., CELL METABOLISM, vol. 33, no. 3, 2021, pages 629 - 648
CRITCHLOW SE ET AL., CANCER RES, vol. 79, 2019
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 February 2003 (2003-02-12), XP002804954, accession no. 488825-99-6 Database accession no. 488825-99-6 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 December 2001 (2001-12-13), XP002804956, accession no. 374915-61-4 Database accession no. 374915-61-4 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 March 2003 (2003-03-13), XP002807513, accession no. 498569-66-7 Database accession no. 498569-66-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 14 December 2001 (2001-12-14), XP002807510, accession no. 375352-28-6 Database accession no. 375352-28-6 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 21 November 2001 (2001-11-21), XP002807509, accession no. 371236-18-9 Database accession no. 371236-18-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 23 March 2003 (2003-03-23), XP002807512, accession no. 500279-77-6 Database accession no. 500279-77-6 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 26 October 2001 (2001-10-26), XP002804955, accession no. 364746-14-5 Database accession no. 364746-14-5 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 6 August 2002 (2002-08-06), XP002807508, accession no. 442643-44-9 Database accession no. 442643-44-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 6 August 2002 (2002-08-06), XP002807511, accession no. 442641-01-2 Database accession no. 442641-01-2 *
DOYEN J ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 451, no. l, 2014, pages 54 - 61
DRAOUI N ET AL., DMM DISEASE MODELS AND MECHANISMS, vol. 4, no. 6, 2011, pages 727 - 32
FUJII W ET AL., ARTHRITIS AND RHEUMATOLOGY, vol. 67, no. 11, 2015, pages 2888 - 96
GAO R ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, 2013, pages 597 - 604
GAO RUI ET AL: "Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, 1 April 2013 (2013-04-01), AMSTERDAM, NL, pages 597 - 604, XP055869080, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2013.01.030 *
GERLINGER M ET AL., JOURNAL OF PATHOLOGY, vol. 227, no. 2, 2012, pages 146 - 56
HASHIMOTO M ET AL., ACS CHEMICAL BIOLOGY, vol. 13, no. 6, 2018, pages 1480 - 86
HE L ET AL., DIS MARKERS, vol. 2018, 2018, pages 2649491
HONG P ET AL., NEUROTOXICOLOGY, vol. 76, 2020, pages 191 - 199
JIM6NEZ-VALERI0 G ET AL., CELL REPORTS, vol. 15, no. 6, 2016, pages 1161 - 74
LYSSIOTIS CA ET AL., TRENDS IN CELL BIOLOGY, vol. 27, no. 11, 2017, pages 863 - 75
MODVIG A ET AL., J ORG CHEM, vol. 79, 2014, pages 5861 - 5868
MURRAY CM ET AL., NATURE CHEMICAL BIOLOGY, vol. 1, no. 7, 2005, pages 371 - 76
PARK H ET AL., BIOORG MED CHEM LETT, vol. 24, no. 3, 2014, pages 835 - 8
PARK HWANGSEO ET AL: "Virtual screening and biochemical evaluation to identify new inhibitors of mammalian target of rapamycin (mTOR)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 3, 27 December 2013 (2013-12-27), pages 835 - 838, XP028819893, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2013.12.081 *
PARKS SK ET AL., ANNUAL REVIEW OF CANCER BIOLOGY, vol. 4, 2020, pages 141 - 58
PEMOVSKA ET AL., NATURE COMMUNICATIONS, 2020
PIATNITSKI EL ET AL., BIOORG MED CHEM LETT, vol. 15, no. 21, 2005, pages 4696 - 8
RABINOWITZ JD ET AL., NATURE METABOLISM, vol. 2, no. 7, 2020, pages 566 - 71
RAN JH ET AL., ACTA PHARMACOLOGICA SINICA, vol. 37, no. 7, 2016, pages 973 - 83
SASAKI S ET AL., PLOS ONE, vol. 8, no. 7, 2013, pages 3 - 9
TODENHOFER T ET AL., MOLECULAR CANCER THERAPEUTICS, vol. 17, no. 12, 2018, pages 2746 - 48
VAN HASSELT PM ET AL., NEW ENGLAND JOURNAL OF MEDICINE, vol. 371, no. 20, 2014, pages 1900 - 1907
WILLIAM JS ET AL., JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 53, no. 11-12, 2010, pages 635 - 644
ZHANG S ET AL., CELL PROLIF, vol. 52, no. 6, 2019, pages e12673
ZHANG S ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 8, 2010, pages 3504 - 10

Similar Documents

Publication Publication Date Title
JP2021521200A (ja) 癌の処置のための化合物
CN109963842A (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
CN111440189B (zh) 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用
CN115057855B (zh) 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
BR112014018868B1 (pt) composto heterocíclico aromático contendo nitrogênio, composição farmacêutica compreendendo dito composto e uso do mesmo
US10590109B2 (en) Heterocyclic compounds used as FGFR inhibitors
BR112017019150B1 (pt) Compostos inibidores de lisil oxidase-like 2 fluorados, composição farmacêutica e uso desses compostos
KR20070115879A (ko) 의학 장애의 치료용 ｃｘｃｒ4 길항제
US20110086868A1 (en) Specific inhibitors for vascular endothelial growth factor receptors
CN110869369B (zh) 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
PT2318389E (pt) Derivados de piridazina como inibidores de smo
NZ537394A (en) Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
CA2723233A1 (fr) Inhibiteurs specifiques des recepteurs du facteur de croissance de l&#39;endothelium vasculaire
BR112016007396B1 (pt) Composto de fórmula (ii), seu processo de preparação e seu uso, composto de fórmula(iia) e composição farmacêutica
MX2008013843A (es) Formulaciones que contienen compuestos de piridazina para tratar enfermedades neuroinflamatorias.
CN107151250B (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用
JP2010506902A (ja) ピリド［２，３−ｄ］ピリミジン類およびキナーゼ阻害剤としてのそれらの使用
JP2019524790A (ja) チエノピリミジン系化合物、その製造方法、医薬組成物およびその応用
BR112017002268B1 (pt) Sal de derivado de piridina monocíclica e cristal do mesmo
CN105722835A (zh) 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用
BR112020021569A2 (pt) Inibidor da interação proteína-proteína mll1-wdr5 de fenil triazol
JP2018508563A (ja) Ｕｓｐ７阻害剤化合物及び使用方法
EP2646427A1 (fr) Dérivés de la quinolin-4(1h)-one en tant qu&#39;inhibiteurs des phosphatidylinositol 3-kinases
TWI226831B (en) Pharmaceutical composition for ameliorating an undesirable anxiety state in a mammal
CN109824664B (zh) 一组抗肿瘤吲哚类生物碱化合物及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22730231

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22730231

Country of ref document: EP

Kind code of ref document: A1